

## CURRICULUM VITAE

**Haralambos P. Gavras, M.D.**

### EDUCATION AND PROFESSIONAL EXPERIENCE:

1962	Graduated - Athens University Medical School
1962-64	Military Service, Internship, Department of Medicine at Military Hospital 424, Salonica, Greece
1964-68	Post-graduate training (Residency), Athens University School of Medicine, Department of Medicine, Hippocraton Hospital
1968-69	Clinical Research Fellow, Renal Unit and Medical Research Council, Blood Pressure Unit, Western Infirmary, Glasgow, United Kingdom
1969-72	Registrar, Medical Research Council Blood Pressure Unit, Western Infirmary, Glasgow, U.K.
1972-74	Research Associate, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York
1974-75	Assistant Professor of Medicine, Cornell University Medical Center, New York; Assistant Attending Physician, New York Hospital
1975-80	Associate Professor of Medicine, Boston University School of Medicine
1975-88	Chief, Hypertension Section, Boston City Hospital
1980-date	Professor of Medicine, Boston University School of Medicine
1988-6/96	Chief, Hypertension and Atherosclerosis Section, University Hospital and Boston City Hospital
7/96-date	Chief, Hypertension and Atherosclerosis Section, Boston Medical Center (Formerly University Hospital and Boston City Hospital).
1996-date	Director, Specialized Center of Research in Molecular Genetics of Hypertension

### AWARDS:

- Andrew W. Mellon Teacher-Scientist Award 1974-75
- Established Investigatorship-American Heart Association 1975-1980
- Arthur C. Corcoran, Lecture-Award of Council of High Blood Pressure Research, American Heart Association, 1993.
- Lewis K. Dahl Memorial Lecture-Award, American Heart Association, 1994.
- Distinguished Physician Award, Hellenic Medical Society, 1995.
- Talal Zein Distinguished Physician Award, Mediterranean Association of Cardiology and Cardiac Surgery, 1999.
- Excellence Award for Hypertension Research sponsored by Novartis, Council of High Blood Pressure Research, American Heart Association, 2000
- Award of the Medal of the City of Athens, Greece, 2001
- Honorary Doctorate, University of Patras School of Medicine, 2003
- Franz Volhard Award & Lectureship Award, World Heart Federation/International Society of Hypertension, 2004
- Honorary Doctorate, Aristotelian University of Thessaloniki School of Medicine, 2007
- Hippocrates Award of the Hellenic Society of Internal Medicine, Athens, Greece, 2007

**Awards (Continued)**

- Honorary Doctorate, Capodistrian University of Athens School of Medicine, 2007.
- Aristoteles Award ,Hellenic Bioscientific Association in the USA. 2011.

**HONORS:**

- British Council Scholarship 1968-69
- Member, Cardiovascular and Renal Study Section, National Institutes of Health, 1983-1987.
- Member, Atherosclerosis, Hypertension & Lipid Metabolism Advisory Committee, National Institutes of Health, 1991-1995.
- Chairman, Program Committee for Council of High Blood Pressure Research of the American Heart Association, 1989-1992.
- President, Inter-American Society of Hypertension, 1995-97
- Chairman of the Council of High Blood Pressure Research of the American Heart Association, 1996-98.
- Fellow of Royal College of Physicians (Glasgow), 1999.
- President, American Society of Hypertension 2002-2004.
- Evans Foundation Symposium in Hypertension, Honoring H. Gavras April 16 2010.

**MEMBERSHIPS:**

- Medical Research Society of Great Britain
- International Society of Hypertension
- European Society of Clinical Investigation
- Inter-American Society of Hypertension
- American Federation for Clinical Research
- Fellow of the Council of Circulation-American Heart Association
- Fellow of the Council of Hypertension-American Heart Association
- Fellow of the American Society of Clinical Pharmacology
- Member, American Society of Clinical Investigation
- Editorial Board for Advances in Therapy, The International Journal of Drug, Device & Diagnostic Research
- Editorial Board, Clinical Physiology and Biochemistry
- Editorial Board, Clinical Experimental Hypertension
- Editorial Board, Hypertension
- Editorial Board, The Open Biochemistry Journal
- Member, European Research Council

**LICENSURE:**

- E.C.F.M.G., 1969
- F.L.E.X. (New York State License), 1974
- Massachusetts License #37784, 1975

**CERTIFICATION:**

- American Board of Internal Medicine, Diplomate, 1978
- Board of Hypertension Specialists, 2000

## CONTRIBUTIONS:

### 1. Pathogenesis of malignant hypertension (clinical and experimental studies)

### 2. Role of angiotensin II (Ang II) in myocardial infarcts and acute renal failure

These experiments proved the cardiotoxic and nephrotoxic properties of Ang II by demonstrating that it can cause myocardial cell necrosis and renal tubular necrosis even in subpressor doses, suggesting mechanism (s) other than BP elevation.

### 3. Reciprocal relationship of renin-Ang II and sodium in BP maintenance

A series of experimental studies in animals with one-kidney or two-kidney renovascular hypertension in early or late stages, as well as clinical studies in patients with salt depletion or repletion, demonstrated that salt availability can determine renin-dependency or sodium-dependency of hypertension. These studies showed why and how even low-or normal-renin hypertensives can be made responsive to medications that block the renin-angiotensin system (RAS).

### 4. Introduction of angiotensin-converting enzyme inhibition (ACEI) and angiotensin receptor blockade (ARB) in the treatment of hypertension and heart failure

A series of animal experiments and clinical studies demonstrated the hemodynamic, hormonal and metabolic effects of acute and chronic treatment with ACEI or ARB in hypertension as well as the greater sensitivity of the vasculature of vital organs to activated RAS and hence the special cardioprotective and nephroprotective effects of this treatment. These results formed the basis for subsequent development of ACEI's and ARB's by the pharmaceutical industry and led to establishment of this approach as standard therapy for hypertension and heart failure.

### 5. Role of vasopressin and sympathetic nervous system (SNS) in salt-induced hypertension

A long series of experiments using wildtype and genetically engineered animals (subsequently confirmed in humans) demonstrated that salt-loading raises the BP not by intravascular fluid volume expansion, but by stimulating pressor hormones, i.e., vasopressin and the SNS; that the central  $\alpha_{2A}$ -adrenergic receptors (ARs) are sympathoinhibitory and the  $\alpha_{2B}$ -ARs are sympathoexcitatory; that inhibition of vasopressin and the central SNS are beneficial in hypertension, heart failure and ischemic heart disease, just as inhibition of the RAS is.

### 6. Role of bradykinin (BK) in cardiovascular disease

These studies proved that ACEI works partly by potentiation of BK; that the beneficial vascular and metabolic effects of BK are due mainly to its B<sub>2</sub>-type receptor (B<sub>2</sub>R), whereas its noxious effects are B<sub>1</sub>R mediated; and that a selective B<sub>2</sub>R agonist has significant cardioprotective effects in ischemic heart disease.

### 7. Genetics of Hypertension

Correlation of clinical phenotypes with genetic profiles lead to identification of certain gene polymorphisms that increase the susceptibility to abnormal BP regulation in various populations.

### 8. Genomics of hypertension

Cellular/molecular studies of intracellular signaling mechanisms mediating cardiovascular tissue damage. Discovery of a novel cardiomyopathy associated gene, named *Cmya 3* or *myomaxin* or *Xirp 2* that mediates ischemic cardiomyopathy, is highly stimulated by Ang II or by coronary obstruction and suppressed by B<sub>2</sub>R activation; may form the basis for a new treatment of ischemic heart disease.

## PUBLICATIONS:

1. Gavras H: The value of different tests in the diagnosis of occlusive renal artery hypertension (clinical and laboratory studies of 29 cases). Thesis, Athens University, 1967.
2. Yatzidis H, Voudiclari S, Oreopoulos D, Tsaparas N, Triantaphyllidis D, Gavras H, Stavroulaka A: Treatment of severe barbiturate poisoning. *Lancet* I:216-217, 1965.
3. Yatzidis H, Gavras H: The diagnostic value of the different tests in hypertension renal vascular disease. *Nosokomiaka Chron.* 30:33-45, 1968.
4. Melleissinos K, Gavras H, Danopoulos E: Thrombocytopenia in the liver cirrhosis resembling idiopathic-thrombocytopenic purpura (Werlhof's disease). *Nosokomiaka Chron* 31:379, 1969.
5. Linton AL, Gavras H, Gleadle RI, Hutchison HE, Lawson DH, Lever AF, MacAdam RF, McNicol GP, Robertson JIS: Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. *Lancet* I:1277-1282, 1969.
6. Gavras H, Brown JJ, Lever AF, Robertson JIS: Changes of renin in individual glomeruli in response to variation of sodium intake in the rabbit. *Clin Sci* 38:409-414, 1970.
7. Brown JJ, Brown WCB, Dusterdieck G, Gavras H, Gleadle RI, Jackson AM, Lawson DH, Lever AF, Linton AL, MacGregor M, MacAdam RF, Prentice E, Robertson JIS, Tree M: Renin and acute renal failure. *Eur J Clin Invest* 1:127, 1970.
8. Lawson DH, MacAdam RF, Singh H, Gavras H, Linton AL: The nephrotoxicity of cephaloridine. *Postgraduate Med J* 46:36-39, 1970.
9. Gavras H, Lawson DH, Linton A: Extended therapy with a trimethoprim-sulphonamide for the treatment of established urinary tract infection. *Scot Med J* 16:506-508, 1971.
10. Gavras H, Brown WCB, Brown JJ, Lever AF, Linton AL, MacAdam RF, McNicol GP, Robertson JIS, Wardrop C: Microangiopathic hemolytic anemia and the development of the malignant phase of hypertension. *Circ Res* 29(Suppl II):127-142, 1971.
11. Gavras H, Brown JJ, Lever AF, MacAdam RF, Robertson JIS: Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. *Lancet* II:19-22, 1971.
12. Gavras H, Brown JJ, Lever AF, MacAdam RF, Robertson JIS: Angiotensin II and renal failure. *Lancet* II:764-765, 1971 (Letter).
13. Gavras H, Brown JJ, MacAdam RF, Lever AF, Robertson JIS: Acute renal failure and tubular necrosis induced in the rabbit by intravenous angiotensin II. *Scot Med J* 16:338, 1971 (Abstract).
14. Brown JJ, Gavras H, Leckie B, Lever AF, MacAdam RF, Morton JJ, Robertson JIS: Acute renal circulatory failure: a probable manifestation of excess renin release. In: Control of Renin Secretion, TA Assaykeen, ed. New York: Plenum Publishing Co. 1971.
15. Brown WCB, Brown JJ, Gavras H, Jackson A, Lever AF, MacGregor J, MacAdam RF, Robertson JIS: Renin and acute circulatory renal failure in the rabbit. *Circ Res* 30:114-122, 1972.

16. Papapatrou PD, Marchant B, Gavras H, Alexander WD: Biliary excretion of <sup>35</sup>S-labeled propylthiouracil methimazole and carbimazole in untreated and pentobarbitone pretreated rats. *Biochem Pharmacol* 21:363-377, 1972.
17. Brown JJ, Chinn RH, Gavras H, Leckie B, Lever AF, MacGregor J, Morton J, Robertson JIS: Renin and renal function. In: Hypertension 1972, J Genest, E Koiw, eds, Berlin: Springer-Verlag, 1972.
18. Leckie B, Gavras H, MacGregor J, Mcelwee G: The conversion of angiotensin I to angiotensin II by rabbit glomeruli. *J Endocr* 55:229-230, 1972.
19. Lawson DH, MacAdam RF, Singh H, Gavras H, Hartz S, Turnbull D, Linton AL: Effect of furosemide on antibiotic-induced renal damage in rats. *J Infect Dis* 126:593-600, 1972.
20. MacGregor J, Briggs JD, Brown JJ, Chinn RC, Gavras H, Lever AF, MacAdam RF, Medina A, Morton JJ, Oliver NWJ, Paton A, Powell-Jackson JD, Robertson JIS, Waite MA: Renin and renal function. International Congress Series #268. *Modern Diuretic Therapy in the Treatment of Cardiovascular and Renal Disease*. Amsterdam: Excerpta Medica, p.71, 1972.
21. Vaughan ED Jr, Gavras H, Laragh JH, Koss MN: Vascular permeability factor: dissociation from the angiotensin II induced pressor and drinking responses. *Nature* 242:334-335, 1973.
22. Gavras H, Brunner HR, Vaughan ED Jr, Laragh JH: Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. *Science* 180:1369-1372, 1973.
23. Buhler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L: Antihypertensive action of propranolol: Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. *Am J Cardiol* 32:511-522, 1973.
24. Vaughan ED Jr, Laragh JH, Gavras I, Buhler FR, Gavras H, Brunner HR, BAER L: Volume factor in low and normal renin essential hypertension: Treatment with either spironolactone or chlorothalidone. *Am J Cardiol* 32:523-532, 1973.
25. Brunner HR, Gavras H, Laragh JH, Keenan R: Hypotensive effects of angiotensin II blockade in man: comparison with propranolol. *Circulation, Suppl* 4:72, 1973 (Abstract).
26. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Keenan R: Angiotensin II blockade, renin secretion and sodium balance in hypertensive man. *Circulation (Suppl 4)*:167, 1973 (Abstract).
27. Brunner HR, Gavras H, Laragh JH, Keenan R: Angiotensin-II blockade in man by sar<sup>1</sup>-ala<sup>8</sup>-angiotensin II for understanding and treatment of high blood-pressure. *Lancet* II:1045-1048, 1973.
28. Gavras H, Brunner HR, Vaughan ED Jr, Laragh JH, Koss M, Cote LJ: Malignant hypertension due to DOCA and salt excess: The role of renin and sodium in development of malignant vascular changes in the rat. *Am Soc Nephrology Sixth Annual Meeting, Washington, D.C., 1973 (Abstract)*.
29. Brown JJ, Gavras H, Kremer D, Lever AF, MacGregor J, Powell-Jackson JD, Robertson JIS: Renin and acute renal failure. *Proceedings of Conference on Acute Renal Failure, State University of New York, Downstate Medical Center. Washington, D.C.: U.S. Government Printing Office, p. 57, 1973.*

30. Oliver N, Gavras H, Aitchison J, Begg C, Briggs JD, Brown JJ, Horton PW, Lee F, Lever AF, Prentice C, Robertson JIS: Microangiopathic hemolytic anemia in malignant hypertension. *Brit Heart J* 863:35, 1973 (Abstract).
31. Prentice CRM, Oliver N, Gavras H, Aitchison J, Begg C, Briggs JJ, Brown JJ, Horton P, Lee F, Lever AF, Robertson JIS: Hemostatic and hematological changes in malignant hypertension. *Proceedings of the 4th International Congress on Thrombosis and Hemostasis, Vienna, p. 204, 1973 (Abstract).*
32. Brunner HR, Gavras H, Laragh JH, Keenan R: Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade. *Circ Res* 34-35 (Suppl I): 35-46, 1974.
33. Brunner HR, Gavras H, Laragh JH: Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. *Progress in Cardiovascular Disease* 17:87-98, 1974.
34. Gavras H, Brunner HR, Laragh JH: Renin and aldosterone and the pathogenesis of hypertensive vascular damage. *Prog Cardiovasc Dis* 17:39-49, 1974.
35. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I: Angiotensin inhibition and the volume-vasoconstrictor interaction in hypertension. 66th Annual Meeting of the Am Soc for Clin Invest 26a, 1974 (Abstract).
36. Vaughan ED Jr, Laragh JH, Gavras I, Buhler FR, Gavras H, Brunner HR, Baer L: The volume factor in low and normal renin essential hypertension. Its treatment with either spironolactone or chlorothalidone. In Hypertension Manual, Laragh JH, ed. New York: Dunn-Donnelly Publ Co., pp. 851-871, 1974.
37. Buhler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L: The antihypertensive action of propranolol: specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. In: Hypertension Manual, Laragh JH, ed. New York: Dunn-Donnelly Publ Co, pp 873-989, 1974.
38. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA: An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. *N Engl J Med* 291:817-821, 1974.
39. Gavras H, Brunner HR: Renin und Natrium und die Entstehung vaskularer Lasionen bei Hypertonie. *Schweiz Med Wschr* 104:1301-1310, 1974.
40. Brunner HR, Gavras H: Renin und Natrium in der Blutdruck-Regulation. *Schweiz Med Wschr* 104:1041, 1974.
41. Gavras H, Brunner HR, Gavras I, Laragh JH: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. *Lancet* II:353, 1974 (Letter).
42. Gavras H, Kremer D, Brown JJ, Gray V, Lever AF, MacAdam RF, Medina A, Morton JJ, Robertson JIS: Angiotensin and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbit and man. *Am Heart J* 89:321-332, 1975.
43. Brunner HR, Gavras H: Clinical implication of renin in the hypertensive patient. *JAMA* 233:1091-1093, 1975.
44. Gavras H, Oliver N, Aitchison J, Begg C, Briggs JD, Brown JJ, Horton PW, Lee F, Lever AF, Prentice C, Robertson Jis: Abnormalities of coagulation and the development of malignant phase hypertension. *Kidney Int* 8:S-252-S-261, 1975.

45. Laragh JH, Sealey JE, Buhler FR, Brunner HR, Vaughan ED Jr, Gavras H, Baer L: The renin axis for understanding and treatment of renovascular and renal hypertension. *Am J Med* 58:4, 1975.
46. Vaughan ED Jr, Buhler FR, Laragh JH, Sealey JE, Gavras H, Baer L: Hypertension and unilateral parenchymal renal disease: evidence for abnormal vasoconstriction-volume interaction. *JAMA* 233:1177-1183, 1975.
47. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, Gavras I: Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. *Circ Res* 36:300-309, 1975.
48. Gavras H, Oliver N, Brown JJ, Aitchison J, Briggs JD, Lee F, Lever AF, Robertson JIS: Microangiopathic hemolytic anemia and the pathogenesis of malignant hypertension. *Kidney Int* 8:S-252, 1975.
49. Gavras H, Brunner HR, Laragh JH, Gavras I, Vukovich RA: The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. *Clin Sci Molec Med (Suppl 2)*: 57s-60s, 1975.

50. Brunner HR, Gavras H: Vascular damage in hypertension. *Hospital Practice* 10:97-108, 1975.
51. Gavras H, Brunner HR, Thurston H, Laragh JH: Reciprocation of renin dependency with sodium volume dependency in renal hypertension. *Science* 188:1316-1317, 1975.
52. Brunner HR, Gavras H: Sodium dependent hypertension. *Medcom* 1975.
53. Paton AM, Lever AF, Oliver NWJ, Medina A, Briggs JD, Morton JJ, Brown JJ, Robertson JIS, Fraser R, Tree M, Gavras H: Plasma angiotensin II, renin, renin-substrate and aldosterone concentrations in acute renal failure in man. *Clin Neph* 3:18-23, 1975.
54. Brunner HR, Gavras H, Laragh JH, Marcus GH, Sealey JE: The risk of low renin hypertension: an updated analysis. *Eur Soc Clin Invest* 53:1975.
55. Gavras H, Brunner HR, Thurston H, Laragh JH, Gavras I: Angiotensin converting enzyme inhibition in the diagnosis and treatment of hypertension in man. Ninth Annual Meeting, *Eur Soc Clin Invest* p 51, 1975 (Abstract).
56. Gavras H, Brunner HR, Thurston H, Laragh JH: Spontaneous transition from renin-dependent to sodium volume-dependent mechanisms in experimental renovascular hypertension. *Clin Res* 23:430, 1975 (Abstract).
57. Brunner HR, Gavras H, Laragh JH, Marcus G, Sealey JE: Renin as a risk factor in hypertension: an updated analysis. Proceedings of Sixth international Congress of Nephrology, Firenze, Italy, #438, June 1975 (Abstract).
58. Brunner HR, Gavras H, Laragh JH: Inhibition of angiotensin II by SAR<sup>1</sup>-Ala<sup>8</sup>-Angiotensin II in hypertensive patients. *Kidney Int* 75:364, 1975 (Abstract).



59. Brunner HR, Gavras H: The role of renin and sodium in high blood pressure regulation. In: Pathophysiology and management of arterial hypertension. G Berglund, I Hansson, L Werko, eds. Molndel, Sweden: AB Hassle, pp. 32-44, 1975.
60. Brunner HR, Gavras H: Pathophysiological concepts of renovascular hypertension. *Contrib Nephrol* 3:20-29, 1976.
61. Gavras H, Oliver JA, Cannon PJ: Interrelation of renin, angiotensin II and sodium in hypertension and renal failure. *Ann Rev Med* 27:485-521, 1976.
62. Gavras H, Ribeiro A, Brunner HR, Gavras I: Evidence of angiotensin and sodium interaction in the three renin subgroups of essential hypertension. *Clin Res* 24:419, 1976 (Abstract).
63. Gavras H, Ribeiro A, Brunner HR, Gavras I: Determination of renin dependency and sodium dependency in the three renin sub-groups of essential hypertension. *Clin Sci Molec Med* 51:197s-200s, 1976.
64. Gavras H, Ribeiro A, Gavras I, Brunner HR: Reciprocal relation between renin dependency and sodium dependency in essential hypertension. *New Engl J Med* 295:1278-1283, 1976.
65. Gavras H, Brunner HR: Renin profiling in hypertension. *New Engl J Med* 295:734, 1976 (Letter).
66. Gavras H, Ribeiro A, Brunner HR, Gavras I: Reciprocation of renin dependency with sodium dependency in the three renin subgroups of essential hypertension. Fourth Meeting of the Int Soc of Hypertens, Sydney, Australia, p 165, 1976 (Abstract).
67. Brunner HR, Gavras H: Les inhibiteurs de l'angiotensine II pour le diagnostic et le traitement de l'hypertension. *Schweiz Med Wschr* 106:1791, 1976.
68. Brunner HR, Gavras H, Ribeiro AB, Posternak L: Angiotensin II blockade in normal man and patients with essential hypertension. *Prog Biochem Pharmacol* 12:145-162, 1976.
69. Posternak L, Brunner HR, Gavras H, Brunner DB: Angiotensin II blockade in normal man. Interaction of renin and sodium in maintaining blood pressure. *Kidney Int* 11:197-203, 1977.
70. Gavras H, Gavras I, Brunner HR, Laragh JH: The antihypertensive action of methyldopa in relation to its effect on the renin aldosterone system. *J Clin Pharmacol* 17:372-378, 1977.
71. Gavras H, Gavras I, Brunner HR, Laragh JH: Effect of a new beta-adrenergic blocker, L-lunolol on blood pressure and on the renin-aldosterone system. *J Clin Pharmacol* 17:350-357, 1977.
72. Gavras H, Gavras I, Cannon PJ, Brunner HR, Laragh JH: Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? *Arch Int Med* 137:1554-1558, 1977.
73. Ferguson RK, Turini GA, Brunner HR, Gavras H, McKinstry D: A specific orally active inhibitor of angiotensin-converting enzyme in man. *Lancet* I:775-778, 1977.
74. Volicer L, Gavras H, L'Donnell A, Chase A; Cyclic nucleotides in brain of spontaneously hypertensive and control rats. *Fed Proc* 36:1050, 1977 (Abstract).
75. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I: Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. *JAMA* 238:880-882, 1977.

76. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H: Improvement of cardiac function by angiotensin II blockade. *Clin Res* 25:258, 1977 (Abstract).
77. Gavras H, Gavras I, Textor S, Volicer L, Brunner HR: Angiotensin converting enzyme inhibition in essential hypertension. *Clin Res* 25:433, 1977 (Abstract).
78. Gavras H, Gavras I, Textor S, Brunner HR: Comparative effects of two different angiotensin inhibitors in essential hypertension. *Clin Res* 25:270, 1977 (Abstract).
79. Jaeger P, Ferguson RK, Brunner HR, Gavras H: Comparison of SQ 20881 and saralasin in normotensive and hypertensive rats. *Kidney Int* 12:75, 1977.
80. Faxon DP, Berkoben J, Gavras H, Flessas A, Ryan TJ: Angiotensin converting enzyme inhibition in patients with congestive heart failure. *Circulation* 55-56 (Suppl III):117, 1977 (Abstract).
81. Hueter D, Schweiger M, Faxon DP, Gavras H, McCormick J, Berger R: Cardiac performance and plasma renin activity in abrupt propranolol withdrawal. *Circulation* 55-56 (Suppl III): 179, 1977 (Abstract).
82. Liang C, Gavras H: Redistribution of regional blood flow after angiotensin converting enzyme inhibition. *Circ* 55-56 (Suppl III): 201, 1977 (Abstract).
83. Brunner HR, Gavras H: Vascular damage in hypertension. In: Hypertension: Mechanisms, Diagnosis and Management, JO Davis, JH Laragh, A Selwyn, eds. New York: HP Publishing Co, pp 169-180, 1977.
84. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H: Congestive heart failure in normotensive man: hemodynamics, renin and angiotensin II blockade. *Brit Heart J* 40:1134-1142, 1978.
85. Gavras H, Gavras I, Textor S, Volicer L, Brunner HR, Rucinska EJ: Effects of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. *J Clin Endocr Metab* 46:220-226, 1978.
86. Chobanian AV, Gavras H, Gavras I, Bresnahan M, Sullivan P, Melby JC: Studies on the activity of the sympathetic nervous system in essential hypertension. *J Human Stress* 4:22-28, 1978.
87. Jaeger P, Ferguson RK, Brunner HR, Kirchertz EJ, Gavras H: Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats. *Kidney Int* 13:239-296, 1978.
88. Liang C, Gavras H, Hood WB Jr: Renin-angiotensin system inhibition in conscious sodium-depleted dogs: Effects on systemic and coronary hemodynamics. *J Clin Invest* 61:874-883, 1978.
89. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tiff CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN: Anti-hypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. *N Engl J Med* 298:991-995, 1978.
90. Gavras H, Liang C, Brunner HR: Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. *Circ Res* 43(Suppl 1): 59-63, 1978.
91. Liang C, Gavras H, Hood W: Systemic and coronary hemodynamic effect of renin-angiotensin system inhibition in sodium depleted dogs. *Amer J Cardiol* 41:394, 1978.

92. Turini GA, Brunner HR, Jaeger P, Ferguson RK, Gavras H: Systolic time intervals in essential hypertension: effects of spirono-lactone and propranolol. *Clin Res* 26:275A, 1978 (Abstract).
93. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tiffit CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN: Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14,225 in man. *Clin Res* 26:289A, 1978 (Abstract).
94. Tiffit CP, Gavras H, Kershaw GR, Gavras I, Cahan D, Brunner HR, Liang C, Chobanian AV: Converting enzyme inhibition in hypertensive emergencies. *Clin Res* 26:370A, 1978 (Abstract).
95. Lappas DG, Gavras H: Plasma renin activity in pulmonary hypertension due to mitral stenosis. *Clin Res* 26:450A, 1978 (Abstract).
96. Brunner HR, Gavras H, Turini GA, Waeber B, Wauters JP: Long-term angiotensin blockade in hypertensive patients with chronic renal failure. *Clin Res* 26:459A, 1978 (Abstract).
97. Liang C, Gavras H, Hemecourt A: Activation of renin-angiotensin system during hypoxia. *Clin Res* 26:484A, 1978 (Abstract).
98. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H: Relationship of plasma norepinephrine to blood pressure, plasma renin activity, mineralocorticoids and plasma volume in essential hypertension. *Clin Res* 26:556A, 1978 (Abstract).
99. Volicer L, O'Donnell A, Gavras H: Increased body temperature and temperature sensitivity in spontaneously hypertensive rats. *Fed Proc* 37:3, 1978 (Abstract).
100. Liang C, Gavras H: Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia: Effects on systemic hemodynamics, regional blood flows, and tissue metabolism. *J Clin Invest* 62:961-970, 1978.
101. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ: Angiotensin converting enzyme inhibition in patients with congestive heart failure. *Circulation* 58:770-775, 1978.
102. Brunner HR, Waeber B, Wauters JP, Turini GA, McKinstry D, Gavras H: Inappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. *Lancet* II:704-707, 1978.
103. Liang C, Gavras H, Brunner HR: Redistribution of regional blood flow after administration of saralasin in salt-depleted dogs. *Clin Sci Molec Med* 55:243s-246s, 1978.
104. Jaeger P, Ferguson RK, Brunner HR, Turini GA, Gavras H: Relationships of renin and aldosterone to antihypertensive effects of spiro-lactone and propranolol. *J Clin Pharmacol* 18:311-318, 1978.
105. Gavras H, Brunner HR: Angiotensin converting enzyme inhibitor in refractory hypertension. *N Engl J Med* 229:363-364, 1978 (Letter).
106. Gavras H, Brunner HR, Gavras I: Angiotensin inhibition: effects on blood pressure and cardiac performance. Seventh International Congress of Nephrology, Montreal, p B-32, 1978 (Abstract).
107. Liang C, Tuttle R, Hood WB, Gavras H: Cardiac conditioning effect of dobutamine. *Circulation (Part II)* 58:255, 1978 (Abstract).

108. Gavras H, Volicer L, Liang C, Tiffit C, Kershaw G, Gavras I, Griffith D, Salit M, Vukovich R, Brunner H: Effects of nadolol in essential hypertension. Eighth World Congress of Cardiology, Tokyo, Japan, p 1033, 1978 (Abstract).
109. Jaeger P, Ferguson RK, Brunner GR, Turini GA, Gavras H, Brunner HR: La tension arterielle, la renine et l'aldosterone au cours d'un essai controle avec la spironolactone et le propranolol, seuls et en association. *La Revue de Medicine* 19:45-51, 1978.
110. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H: Angiotensin II blockade in congestive heart failure. *Arch Int Pharmacodyn Therapie* 233:166-176, 1978.
111. Brunner HR, Jaeger P, Ferguson RK, Jequier E, Turini GA, Gavras H: Need for beta-blockade in hypertension reduced with long-term minoxidil. *Brit Med J* 2:385-388, 1978.49.
112. Turini GA, Brunner HR, Ferguson JI, Rivier JL, Gavras H: Renin and hemodynamic effects of saralasin in normotensive patients with chronic congestive heart failure. *Kidney Int* 13:539, 1978 (Abstract).
113. Jaeger P, Brunner HR, Turini GA, Jequier E, Ferguson RK, Gavras H: Minoxidil a long terme: renine, aldosterone, noradrenaline et besoin de B-bloquants. *Schweiz Med Wschr* 18:1707-1709, 1978.
114. Waeber B, Gavras H, Brunner HR, Chappuis P, Gavras I: Traitement chronique de l'hypertension arterielle par un inhibiteur de l'enzyme de conversion de l'angiotensine. *Schweiz Med Wschr* 108:1980-1983, 1978.
115. Gavras H, Gavras I: Angiotensin inhibition: a new approach to the treatment of hypertension. *Iatriki* 34:521-525, 1978.
116. Waeber B, Guignard JP, Brunner HR, Turini GA, Gavras H: Treatment of severe renal hypertension in a child with an inhibitor of the angiotensin converting enzyme (SQ 14, 225). *Helvetica Paediatrica Acta, Suppl* 40:10-11, 1978 (Abstract).
117. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H. Relationship of basal plasma noradrenaline to blood pressure, age, sex, plasma renin activity and plasma volume in essential hypertension. *Clin Sci Molec Med* 55:93s-96s, 1978.
118. Brecher P, Trtvusl A, Gavras H, Chobanian AV: Peptidyl dipeptidase in rabbit brain microvessels. *Biochem Biophys Acta* 526:537-546, 1978.
119. Brunner HR, Gavras H, Turini GA, Waeber B, Chappuis P, McKinstry DN: Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. *Clin Sci Molec Med* 55:293s-295s, 1978.
120. Textor S, Gavras H, Tiffit CP, Bernard D: Norepinephrine and plasma renin activity in chronic renal failure: evidence for interacting roles in hemodialysis hypertension. *Kidney Int* 14:704, 1978 (Abstract).
121. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H: Relationship of basal plasma norepinephrine to blood pressure, plasma renin activity, mineralocorticoids, and plasma volume in essential hypertension. *Trans Assoc Amer Phys* 91:368-380, 1978.
122. Gavras H, Gavras I, Textor S, Tiffit CP, Kershaw GR, Brunner HR: The use of SQ 20881 converting enzyme inhibitor (teprotide) for diagnostic purposes in hypertension. *Cardiovasc Med* (in press).

123. Brecher PI, Tercyak A, Gavras H, Chobanian AV: Angiotensin-converting enzyme activity in cerebral microvessels. *Fed Proc* 37:3 (Abstract).
124. Gavras H, Gavras I, Brunner HR, Liang C: Physiologic studies with saralasin in animals. *Kidney Int* 15:S-20-S-28, 1979.
125. Gavras I, Gavras H, Sullivan P, Tiffet CP, Chobanian AV, Brunner HR: A comparative study of the effects of oxprenolol versus propranolol in essential hypertension. *J Clin Pharmacol* 19:8-14, 1979.
126. Brunner HR, Gavras H, Waeber B, Kershaw G, Turini GA, Vukovich R, McKinstry DN, Gavras I: Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. *Ann Int Med* 90:19-23, 1979.
127. Waeber B, Brunner HR, Turini GA, Curtet N, Keller I, Gavras H: Potentialisation de l'effet antihypertenseur du captopril par les diurétiques. *Annales de Cardiologie et Angiologie* 28:9-11, 1979.
128. Brunner HR, Waiters JP, Waeber B, Gavras H: The renin angiotensin system in hypertensive patients with chronic renal failure. In *mitteilungen der Arbeitsgemeinschaft für Klin. Nephrologie* 8:4-14, 1979.
129. Tiffet CP, Gavras H, Kershaw GR, Gavras I, Brunner HR, Liang C, Chobanian AV: Converting enzyme inhibition in hypertensive emergencies. *Ann Int Med* 90:43-47, 1979.
130. Gavras I, Gavras H, Brunner HR, Liang C: Antihypertensive action of  $\alpha$ -adrenoceptor blockade and the renin-angiotensin system. *Brit J Clin Pharmacol* 7 (suppl 2):213s, 1979.
131. Volicer L, Liang CS, Gavras H, Tiffet CP, Kershaw GR, Gavras I, Griffith DL, Vukovich R, Brunner HR: Effect of nadolol in treatment of hypertension. *J Clin Pharmacol* 19:137-47, 1979.
132. Volicer L, O'Donnell A, Gavras H: Cyclic nucleotide levels in brains of control and hypertensive rats. *Life Sci* 24:131-136, 1979.
133. Creager MA, Faxon DP, Halperin JL, Gavras H, Coffman JD, Ryan TJ: Effects of angiotensin inhibition and peripheral hemodynamics in congestive heart failure. *Clin Res* 27:106A, 1979 (Abstract).
134. Kowaloff H, Gavras H, Brecher P: Evidence for the vascular localization of brain renin. *Clin Res* 27:315A, 1979 (Abstract).
135. Turini GA, Waeber B, Curtet N, Gavras H: Long-term cardiac responses of hypertensive patients treated by an inhibitor of angiotensin converting enzyme. *Clin Res* 27:319A, 1979 (Abstract).
136. Liang C, Gavras H: The role of sympathetic nervous system in mediating the systemic and coronary hemodynamic responses to acute renal artery stenosis. *Clin Res* 27:468A, 1979 (Abstract).
137. Turini GA, Brunner HR, Gribic M, Belaloye A, Rivier JL, Waeber B, Gavras H: Acute improvement of cardiac function by captopril in patients with refractory congestive heart failure. *Clin Res* 27:209A, 1979 (Abstract).
138. Waeber B, Brunner HR, Turini GA, Curtet N, Gavras H: Blood pressure control by captopril despite intermittent normalization of angiotensin converting enzyme activity. *Clin Res* 27:319A, 1979 (Abstract).

139. Chobanian AV, Tiffit CP, Gavras H, Volicer L: Studies on the mechanism of fludrocortisone-induced hypertension in patients with chronic orthostatic hypertension. *Clin Res* 27:511A, 1979 (Abstract).
140. Faxon DP, Sussman HA, Gavras H, Liang C, Ryan TJ: The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in normal patients. *Amer J Cardiol* 43:406, 1979 (Abstract).
141. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H: Improvement of chronic congestive heart failure by oral captopril. *Lancet* I:1213-1215, 1979.
142. Chobanian AV, Volicer L, Tiffit CP, Gavras H, Liang C, Faxon D: Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. *N Engl J Med* 301:68-73, 1979.
143. Brunner HR, Waeber B, Gavras H: Rational use of captopril. *Lancet* I:832, 1979 (Letter).
144. Liang C, Tuttle RR, Hood WB, Gavras H: Conditioning effects of chronic infusions of dobutamine. *J Clin Invest* 64:613-619, 1979.
145. Brunner HR, Gavras H, Volicer L, Turini FA, McKinstry DM, Vukovich RA, Gavras I: Orally active angiotensin converting enzyme inhibition (SQ 14,225) as a treatment for essential hypertension. *Brit J Clin Pharmacol* 7(Suppl 2):205S-211S, 1979.
146. Wauters JP, Waeber B, Brunner HR, Turini GA, Guignard JP, Gavras H: Captopril and salt subtraction to treat "uncontrollable" hypertension in hemodialysis patients. *Proceedings of European Dialysis and Transplantation Association* 16:610-614, 1979.
147. Gavras H, Gavras I, Brunner HR: Converting enzyme inhibition in the diagnosis and treatment of hypertension. In: Controversies in Nephrology - 1979, Vol. 1, GE Schreiner, JF Winchester, W Mattern, BF Mendelson, eds. Washington DC, pp. 260-268.
148. Brunner HR, Waeber B, Ferguson RK, Turini GA, Gavras H: The position of betablockers in antihypertensive therapy. comparison with other antihypertensive agents. *Cardiology* 64 (Suppl 1):88-93, 1979.
149. Gavras H, Gavras I, Brunner HR: Angiotensin inhibitors for hypertension. *Comprehensive Therapy* 6:14-18. 1980.
150. Gavras H: Congestive heart failure: treatment by angiotensin blockade. *Primary Cardiol* 6:103-113, 1980.
151. Kowaloff H, Gavras H, Brecher P: Reninlike enzymatic activity in the cerebral microvessels of the rat. *Am J Physiol* 238:H384-H388, 1980.
152. Faxon DP, Creager MA, Halperin JL, Gavras H, Coffman JD, Ryan TJ: Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. *Circulation* 61:925-931, 1980.
153. Gavras H, Gavras I, Hadzinikolaou P, Brunner HR: Inhibition of angiotensin conversion: its role in treatment of hypertension and congestive heart failure. *J Cardiovasc Med* 5:327-335, 1980.
154. Gavras I, Gavras H: Special considerations in treating hypertension in the elderly. *Geriatrics* 35:34-40, 1980.
155. Brunner HR, Gavras H, Waeber B, Textor S, Turini GA: Clinical use of an orally acting converting enzyme inhibitor: captopril. *Hypertension* 2:558-566, 1980.

156. Gavras H, Gavras I, Hatzinikolaou P, Brunner HR: Converting enzyme inhibition in human hypertension. Sixth International Congress of Endocrinology, Melbourne, Australia, p. 141, 1980 (Abstract).
157. Waeber B, Brunner HR, Brunner DB, Curtet A, Turini GA, Gavras H: Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. *Hypertension* 2:236-242, 1980.
158. Gavras H, Liang C: Acute renovascular hypertension in conscious dogs. Interaction of the renin-angiotensin system and sympathetic nervous system in systemic hemodynamics and regional blood flow responses. *Circ Res* 47:356-365, 1980.
159. Brunner HR, Waeber B, Turini GA, Wauters JP, Gavras H: Clinical use of captopril in patients with hypertension or congestive heart failure. *Pharm Clin Exper* (in press).
160. Gavras H, Gavras I, Textor S, Tiffit CP, Kershaw GR, Brunner HR: The use of SQ 20881 converting enzyme inhibitor (teprotide) for diagnostic purposes in hypertension. In: Captopril and Hypertension. D Case, E Sonnenblick, JH Laragh, eds. New York: Plenum Medical Book Company, 210-214, 1980.
161. Bresnahan MR, Hatzinikolaou P, Brunner HR, Gavras H: Effect of tyrosine infusion in normotensive and hypertensive rats. *Am J Physiol* 239:H206-H211, 1980.
162. Bresnahan MR, Hatzinikolaou P, Gavras H, Brunner HR: Catecholamine levels and the hypotensive effect of tyrosine in rats. *Clin Res* 28:329A, 1980 (Abstract)
163. Textor S, Brunner HR, Gavras H: Bradykinin and angiotensin: evidence for a specific interaction in vivo. *Clin Res* 28:337A, 1980 (Abstract).
164. Hatzinikolaou P, Gavras H, Gavras I, Manning M, Brunner HR: Mechanism of sodium-induced elevation of blood pressure in the anephric state. *Clin Res* 28:447A, 1980 (Abstract).
165. Hatzinikolaou P, Gavras H, Manning M, Brunner HR, Gavras I: Role of vasopressin and adrenergic system in renoprival hypertension in rats. *Clin Res* 28:448A, 1980 (Abstract).
166. Liang CS, Yi M, Gavras H, Goodman M, Hood W: Systemic hemodynamic effects of acute thiamine inhibition. *Clin Res* 28:468A, 1980 (Abstract).
167. Brunner HR, Waeber B, Gavras H, Brunner DB: Zweckmassige Anwendung von Diuretika in der Behandlung der Arteriellen Hypertonie. In: Diuretika, J Rosenthal, H, Knauf, eds. Weinheim, Germany: Edition Medizin, 1980. pp. 307-318.
168. Waeber B, Brunner HR, Gavras H: Les inhibiteurs de l'enzyme de conversion de l'angiotensine: implications pathogeniques et therapeutiques dans l'hypertension arterielle. In: Actualites Nephrologiques de l'Hopital Necker. Belgium: Flammarion, 1980.
169. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I: Sodium-induced elevation of blood pressure in anephric rats. *Science* 209:935-936, 1980.
170. Brunner HR, Gavras H, Waeber B: Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. *Clin Exper Hypertension* 2:639-657, 1980.
171. Hatzinikolaou P, Gavras H, Brecher P: Increased tyrosine transport across the blood-brain barrier during chronic experimental hypertension. *Circulation* 62, Suppl III:188, 1980 (Abstract).

172. Waeber B, Gavras I, Brunner HR, Cook CA, Gavras H: Immediate and sustained blood pressure response to oral converting enzyme inhibition. Relationship to renin. *Circulation* 62, Suppl III:188, 1980 (Abstract).
173. Brunner HR, Gavras H: Is the renin system necessary? *Am J Med* 69:739-745, 1980.
174. Textor SC, Brunner HR, Gavras H: Converting enzyme inhibition during chronic angiotensin II infusion in rats: evidence against a non-angiotensin mechanism. *Clin Sci* 59:71-74s, 1980.
175. Volicer L, Volicer BJ, Gavras H: The effect of alcohol intake on compliance with antihypertensive treatment. In: Alcoholism: A Perspective. FS Messiha, GS Tyner, eds. Westbury, New York: PJD Publications Ltd., 88-99, 1980.
176. Brunner HR, Gavras H, Waeber B, Turini GA, Wauters JP: Captopril an oral angiotensin converting enzyme inhibitor active in man. In: Captopril and Hypertension. DB Case, EH Sonnenblick, JH Laragh, eds. New York: Plenum Medical Book Company, 1980, pp 149-172.
177. Gavras H: Angiotensin inhibition for the characterization and treatment of arterial hypertension. Proceedings of the First Panhellenic Congress of Nephrology, Thessaloniki, March 1980.
178. Gavras I, Gavras H, Tiffet CP, Kershaw GR, Bresnahan M: Effect of pindolol on blood pressure, plasma renin activity and catecholamines in hypertensive patients. *J Clin Pharmacol* 21:79-83, 1981.
179. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I: Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. *Am J Physiol* 240:H827-H831, 1981.
180. Waeber B, Brunner HR, Wauters JP, Gavras H: Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension. In: Advances in Nephrology from the Necker Hospital. Vol 10, MH Maxwell, J. Hamburger, J Crosnier, JP Grunfeld, eds. Chicago: Year Book Publishers, pp. 111-133, 1981.
181. Gavras H, Waeber B, Kershaw GR, Liang C, Textor S, Brunner HR, Tiffet CP, Gavras I: Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. *Hypertension* 3:441-447, 1981.
182. Liang C, Yi M, Sherman LG, Black J, Gavras H, Hood WB: Dobutamine infusion in conscious dogs with and without acute myocardial infarction. Effects on systemic hemodynamics, myocardial blood flow and infarct size. *Circ Res* 49:170-180, 1981.
183. Creager MA, Halperin JL, Bernard DB, Faxon DP, Melidossian CD, Gavras H, Ryan TJ: Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive cardiac failure. *Circulation* 64:483-489, 1981.
184. Brunner HR, Turini GA, Waeber B, Gavras H: Clinical pharmacological studies with captopril. In: Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications, ZP Horowitz, ed. Baltimore: Urt and Schwarzenberg, 1981.
185. Spertini F, Brunner HR, Waeber B, Gavras H: Opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs norepinephrine in rats. *Circ Res* 48:612-618, 1981.



186. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Ferber F, Gomez H, Jones K, Gavras H, Brunner HR: Three new long-acting converting enzyme inhibitors. Relationship between plasma converting enzyme activity and response to angiotensin I in normal volunteers. *J Clin Exper Therapeutics* 29:665-670, 1981.
187. Waeber B, Brunner HR, Burckardt P, Gavras H: Hypertension in a patient with hypercalcemia. *Arch Int Med* 142:143-145, 1982.
188. Hatzinikolaou P, Gavras H, Waeber B, Fisher GH, Ryan JW: Comparative study of three parenteral inhibitors of the angiotensin converting enzyme. *Biochem Pharmacol* 30:1869-1872, 1981.
189. Textor SC, Gavras H, Tiffit CP, Bernard DB, Idelson B, Brunner HR: Norepinephrine and renin activity in chronic renal failure. Evidence for interacting roles in hemodialysis hypertension. *Hypertension* 3:294-299, 1981.
190. Gavras H, Charocopos F, Brunner HR, Gavras I: Angiotensin converting enzyme inhibition: a new therapeutic modality. *Bull NY Acad Med* 57:304-310, 1981.
191. Gavras I, Graff L, Rose BD, McKenna JM, Brunner HR, Gavras H: Fatal pancytopenia associated with the use of captopril. *Ann Int Med* 94:58-59, 1981.
192. Gavras H, Gavras I: The renin angiotensin system in hypertension. In: Contemporary Issues in Nephrology 8:65-99, Hypertension, BM Brenner, JH Stein, eds. New York: Churchill, Livingston, 1981.
193. Brunner HR, Waeber B, Turini GA, Wauters JP, Brunner DB, Gavras H: Position paper: angiotensin-converting enzyme blockade as a therapeutic modality. In: Frontiers in Hypertension Research, JH Laragh, F Buhler, DW Seldin, eds. New York: Springer-Verlag, pp 503-516, 1981.
194. Gavras H, Gavras I, Brunner HR: Vasoconstriction and sodium volume factors in renovascular hypertension. In: Frontiers in Hypertension Research, JH Laragh, F Buhler, DW Seldin, eds. New York: Springer-Verlag pp 159-164, 1981.
195. Gavras H, Gavras I, Brunner HR: Hypertension, vasopressors and the susceptibility to vascular injury: experimental and clinical studies. In: Frontiers in Hypertension Research, JH Laragh, F Buhler, DW Seldin, eds. New York: Springer-Verlag, 1981.
196. Hatzinikolaou P, Gavras I, Gavras H, Brunner HR, Bresnahan MR: Relationship between vasopressin-induced vasoconstriction, catecholamines and intravascular fluid volume changes in experimental saline-induced hypertension. *Rev Med Chile* 109:14s, 1981 (Abstract).
197. Gavras H, Waeber B, Kershaw GR, Liang C, Brunner HR, Gavras I: Role of reactive hyperreninemia in the blood pressure changes induced by sodium depletion in patients with refractory hypertension. *Rev Med Chile* 109:30s, 1981 (Abstract).
198. Bass TA, Faxon DP, Halperin JL, Creager MA, Melidossian CD, Gavras H, Ryan TJ: Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure. *Clin Sci* 29:176A, 1981 (Abstract).
199. Charocopos F, Hatzinikolaou P, North WG, Gavras H: Effects of endogenous vasopressin stimulation on systemic hemodynamics and regional blood flows. *Clin Sci* 29:181A, 1981 (Abstract).

200. Biollaz J, Burnier M, Schelling JL, Turini GA, Jones KH, Lutterbeck P, Gavras H, Brunner HR: MK 421 and its lysine analog: two new converting enzyme inhibitors in normal man. *Clin Sci* 29:269A, 1981 (Abstract).
201. Gavras H, Hatzinikolaou P, North WG, Gavras I: Evidence for dopaminergic regulation of vasopressin release. *Clin Sci* 29:291A, 1981 (Abstract).
202. Burnier M, Brunner HR, Gavras H: Angiotensin II and isoproterenol decrease the pressor effect of lysine-vasopressin in conscious rats. *Clin Sci* 29:355A, 1981 (Abstract).
203. Richter EA, Belur E, Gavras H, Galbo H, Goodman MN, Ruderman NB: Muscle Glycogenolysis During Exercise: Dual Contact by Epinephrine and Contractions. *Clin Sci* 29:419A, 1981 (Abstract).
204. Gavras H, Andrews P, Papadakis N: Reversal of experimental delayed cerebral vasospasm by angiotensin converting enzyme inhibition. *Clin Sci* 29:430A, 1981 (Abstract).
205. Waeber B, Black J, Bresnahan R, Brunner HR, Gavras H: Central and/or peripheral inhibition of phenylethanolamine-N-methyltransferase in normotensive and hypertensive rats. *Clin Sci* 29:525A, 1981 (Abstract).
206. Gavras H, Gavras I, Brunner HR: Clinical relevance of reactive hyperreninemia. *Res and Staff Phys* 27:65-72, 1981.
207. Textor S, Brunner HR, Gavras H: Evidence for bradykinin potentiation by angiotensin congeners in conscious rats. *Am J Physiol* 240:H255-H261, 1981.
208. Doherty JU, Liang C, Faillace RT, Yi M, Arnold S, Gavras H, Hood WB Jr: Inotropic and chronotropic effects of insulin in the conscious dog: contributions of catecholamines and hypoglycemia. *Am J Cardiol* 47:460, 1981.
209. Faxon DP, Halperin JL, Creager MA, Gavras H, Schick EC, Ryan T: Angiotensin inhibition in severe heart failure: acute renal central and limb hemodynamic effects of captopril with observations on sustained oral therapy. *Am Heart J* 101:548-556, 1981.
210. Brunner HR, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JI: Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. *Br J Clin Pharmacol* 11:461-467, 1981.
211. Gavras H, Andrews P, Papadakis N: Reversal of experimental delayed cerebral vasospasm by angiotensin enzyme inhibition. *J Neurosurg* 55:884-888, 1981.
212. Gavras I, Hatzinikolaou P, Charocopos F, Brunner HR, Gavras H: Effects of beta-adrenoceptor blockade on systemic and regional hemodynamics in intact and anephric rats. Eighth International Congress of Pharmacology. Tokyo: IUPHAR, p 332, 1981 (Abstract).
213. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO: Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". *Lancet* II: 543-546, 1981.
214. Hatzinikolaou P, Brecher P, Gavras H: Chronic hypertension increases tyrosine transport across the blood-brain barrier in the rat. *Life Sci* 29:1657-1660, 1981.
215. Textor SC, Brunner HR, Gavras H: Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. *Hypertension* 3:269-276, 1981.

216. Gavras H, Biollaz JH, Waeber B, Brunner HR, Gavras I, Davies RO, Gomez H, Abrams WB: Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421." Eighth Scientific Meeting of the Int Soc Hypertens, Milan, #148, 1981 (Abstract).
217. Biollaz J, Burnier M, Turini GA, Gomez HJ, Ferber F, Charocopos F, Jones KH, Lutterbeck P, Gavras H, Brunner HR: Effect of three new long-acting converting-enzyme inhibitors administered orally to healthy volunteers. Am Soc Clin Pharmacol and Therapeutics, 82nd Annual Meeting, New Orleans, 1981, p 6 (Abstract).
218. Dippette D, Waeber B, Volicer L, Gavras H: Salt-induced hypertension of chronic renal failure: evidence for a central neurogenic mechanism. Circulation 64:224, 1981 (Abstract).
219. Gavras H, Hatzinikolaou P, Brunner HR, Gavras I: Clinical applications of angiotensin blockade. Eighth International Congress of Nephrology, Athens. W Zurukzollu, M Pyrpasopoulos, M Sion, C Zamboulis, eds. Basel: S Karger, 1981, pp. 1060-1066.
220. Brunner HR, Gavras H: Medical therapy of renovascular hypertension. Eighth International Congress of Nephrology, Athens, W Zurukzoglou, M Papadimitriou, M Pyrpasopoulos, M Sion, C Zamboulis, eds. Basel: S Karger 1981, pp. 1139-1145.
221. Wauters JP, Waeber B, Brunner HR, Guignard JP, Turini GA, Gavras H: Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol 16:86-92, 1981.
222. Waeber B, Gavras I, Brunner HR, Gavras H: Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol 21:508-516, 1981.
223. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Sackel H, Charocopos F, Davies RO: Effects of the oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. Clin Sci 61:281s-283s, 1981.
224. Gavras H, Brunner HR, Gavras I: Captopril in the treatment of hypertension. Ann Int Med 95:505-506, 1981 (Editorial).
225. Black J, Waeber B, Bresnahan M, Gavras I, Gavras H: Blood pressure response to central and/or peripheral inhibition of phenylethanolamine-N-methyltransferase in normotensive and hypertensive rats. Circ Res 49:518-524, 1981.
226. Gavras H, Gavras I: Leukopenia: Idiopathic or drug-induced? New Engl J Med 306:484, 1982 (Letter).
227. Burnier M, Turini GA, Brunner HR, Porchet M, Kruithof D, Vukovich RA, Gavras H. RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. Brit J Clin Pharmacol 12: 893-899, 1981.
228. Gavras H: Essential hypertension. In: Clinical Hypertension and Hypotension. HR Brunner, H. Gavras, eds. New York: Marcel Dekker, 1982.
229. Brunner HR, Gavras H: Renin and angiotensin II, aldosterone, salt and the kidney. In: Clinical Hypertension and Hypotension. HR Brunner, H Gavras, eds. New York: Marcel Dekker Inc., 1982.
230. Richter EA, Ruderman NB, Gavras H, Belur ER, Galbo H: Muscle glycogenesis during exercise: dual control by epinephrine and contractions. Am J Physiol 242:E25-E-32, 1982.

231. Liang C, Doherty JU, Faillace R, Maekawa K, Arnold S, Gavras H, Hood WB Jr: Insulin infusion in conscious dogs: effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. *J Clin Invest* 69:1321-1336, 1982.
232. Gavras H, Gavras I, Brunner HR: Orally active converting enzyme inhibitors in hypertension and congestive heart failure. *Adv Exp Med Biol* (in press).
233. Biollaz J, Durr J, Brunner HR, Prochet M, Gavras H: Escape from mineralocorticoid-excess: the role of angiotensin II. Ninth Scientific Meeting of the Int Soc Hypertens, 1982, p. 44 (Abstract)
234. Brunner HR, Gavras H: eds, Clinical Hypertension and Hypotension. New York: Marcel Dekker Inc. 1982.
235. Burnier M, Biollaz J, Brunner HR, Gavras H: Vasopressin blood pressure dependency following beta-adrenoceptor blockade in normotensive and mineralocorticoid-salt hypertensive rats. Ninth Scientific Meeting of the Int Soc Hypertens, 1982, p. 61.
236. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I: Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure in the rat. Ninth Scientific Meeting of the Int Soc Hypertens, 1982, p. 134 (Abstract).
237. Waeber B, Bresnahan MR, Gavras I, Gavras H: Antihypertensive effect of the centrally acting PNMT inhibitor SKF 64139 in glucocorticoid hypertension. Ninth Scientific Meeting of the Int Soc Hypertens, 1982, p. 432 (Abstract).
238. Waeber B, Gavras H, Gavras I, Bresnahan MR: Sodium-induced activation of central neurogenic mechanisms in one kidney, one-clip renal hypertensive rats. Ninth Scientific Meeting of the Int Soc Hypertens, 1982, p. 433 (Abstract).
239. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO: Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. *Clin Exper Hyper Theory and Practice* A4(1-2):303-314, 1982.
240. Burnier M, Biollaz J, Brunner HR, Turini GA, Gavras H: Comparison in normal volunteers of three converting enzyme inhibitors RHC 3659, MK-421, and captopril. *Am J Cardiol* 49:1550-1551, 1982.
241. Dipette D, Gavras I, North WG, Brunner HR, Gavras H: Vasopressin in salt-induced hypertension of experimental renal insufficiency. *Hypertension* 4:II-125-II-130, 1982.
242. Liang C, Gavras H, Black J, Sherman LG, Hood WB: Renin-angiotensin system inhibition in acute myocardial blood flow, segmental myocardial function, and infarct size. *Circulation* 66:1249-1255, 1982.
243. Andrews P, Papadakis N, Gavras H: Reversal of experimental acute cerebral vasospasm by angiotensin enzyme inhibition. *Stroke* 13:480-483, 1982.
244. Charocopos F, Hatzinikolaou P, North WG, Gavras H: Systemic and regional hemodynamic effects of endogenous vasopressin stimulation in rats. *Am J Physiol* 12:H560-565, 1982.
245. Barbey JT, Love J, Flessas AP, Barry T, Gavras H: Plasma catecholamines during spontaneous angina. *Clin Res* 30:170, 1982 (Abstract).
246. Charocopos F, Hatzinikolaou P, Brunner HR, Gavras H: Comparison of regional blood flows in various models of experimental hypertension. *Clin Res* 30: 177, 1982 (Abstract).

247. Charocopos F, Gavras I, Brunner HR, Gavras H: Systemic and regional hemodynamics in the streptozotocin diabetic rat. *Clin Res* 30:509, 1982 (Abstract).
248. Dipette D, Dipette P, North WG, Gavras I, Brunner HR, Gavras H: Plasma vasopressin response to hyperosmotic solution (renograffin) and its effect on blood pressure in quadriplegic patients. *Clin Res* 30:510, 1982.
249. Gavras H, Hatzinikolaou P, North WG, Bresnahan MR, Gavras I: Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. *Hypertension* 4:400-405, 1982.
250. Gavras H: Possible mechanisms of sodium-dependent hypertension: volume expansion or vasoconstriction? *Clin Exp Theory and Practice* A4(4&5):737-749, 1982.
251. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme inhibition. *J Cardiovasc Pharmacol* 4:966-972, 1982.
252. Hatzinikolaou P, Gavras I, North WG, Brunner HR, Gavras H: Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure in rats. *Clin Sci* 63:313s-317s, 1982.
253. Gavras I, Gavras H, Chobanian AV, Tiff CP, Melby JC, Jick H: Hypertension and age: clinical and biochemical correlates. *Clin Exper Hyper Theory and Practice* A4(7):1097-1106, 1982.
254. Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras H: Prediction of sustained antihypertensive efficacy of chronic captopril therapy relationships to immediate blood pressure response and control plasma renin activity. *Am Heart J* 103:384-390, 1982.
255. Waeber B, Brunner HR, Haeusler G, Gavras H: Pre- and postsynaptic effects of SKF64139, a phenylethanolamine N-methyltransferase inhibitor, in conscious normotensive rats. *J Cardiovasc Pharmacol* 4:659-764, 1982.
256. Faxon DP, Creager MA, Halperin JL, Sussman HA, Gavras H, Ryan TJ: The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. *Int J Cardiol* 2:251-262, 1982.
257. Halperin JL, Faxon DP, Creager MA, Bass TA, Melidossian CD, Gavras H, Ryan TJ: Coronary hemodynamic effects of angiotensin inhibition in patients with congestive heart failure. *Am J Cardiol* 50:967-972, 1982.
258. Waeber B, Gavras H, Gavras I, Chao P, Kohlmann O Jr, Bresnahan MR, Brunner HR, Vaughan D: Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats. *J Pharmacol Exper Ther* 233:510-515, 1982.
259. Frohlich ED, Maxwell MH, Baer L, Gavras H, Hollifield JW, Krakoff LR, Lifschitz MED, Logan A, Poutasse E, Streeten DHP: Use of saralasin as a diagnostic test in hypertension: report of a consensus committee. *Arch Int Med* 142:1437-1440, 1982 (Editorial).
260. Burnier M, Biollaz J, Brunner HR, Gavras H: Vasopressin blood pressure dependency after alpha-adrenoceptor blockade in normotensive and mineralocorticoid salt hypertensive rats. *Clin Sci* 101s-103s, 1982.
261. Waeber B, Brunner HR, Gavras H: The renin-angiotensin system and its inhibition in the treatment of hypertension. In: Hypertension, P Sleight, ED Freis, eds. London: Butterworth Scientific, 1982, pp. 293-305.

262. Burnier M, Biollaz DB, Gavras H, Brunner HR: Alpha and beta adrenoceptor blockade in normotensive and deoxycorticosterone (DOC)-hypertensive rats; plasma vasopressin and vasopressin pressor effect. *J Pharmacol Exper Ther* 224:222-227, 1982.
263. Brunner HR, Waeber B, Biollaz J, Gavras H: Acute and long-term inhibition of the renin-angiotensin system. In: Mechanisms of action of antihypertensive drugs. CT Dollery, ED Frohlich, eds. Guadalajara, Mexico, 1982.
264. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I: Clinical application of orally active angiotensin converting enzyme inhibitors. In: Mechanisms of action of antihypertensive drugs. CT Dollery, ED Frohlich, eds. Guadalajara, Mexico, 1982.
265. Gavras H: Hypertension and congestive heart failure: benefits of converting enzyme inhibition (captopril). *J Am Coll Cardiol* 2:518-520, 1983.
266. Dipette D, Waeber B, Volicer L, Chao P, Gavras I, Gavras H, Brunner HR: Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. *Life Sci* 32:733-740, 1983.
267. Gavras H, Gavras I: Hypertension in the elderly. Boston: John Wright PS Inc 1983.
268. Kohlmann O Jr, Catsimpoolas N, Griffith AL, Gavras H: Plasma fibronectin levels in benign and malignant experimental hypertension. *Clin Res* 31:488A, 1983 (Abstract).
269. Faxon D, Creager MA, Weiner DA, Melidossian DC, Cutler SS, Dagostino G, Coats W, Gavras H, Bass T, Ryan TJ: Captopril improves myocardial oxygen demand at rest and exercise in patients with severe heart failure. *Clin Res* 31:181A, 1983. (Abstract).
270. Gavras H, Bain GT, Bland LI, Gavras I: Hypertensive response to saline microinjection in the nucleus tractus solitarius. *Clin Res* 31:487A, 1983 (Abstract).
271. Gavras I, Gavras H: Captopril and Enalapril. *Ann Int Med* 98:556-557, 1983 (Letter).
272. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I: Clinical application of orally active angiotensin converting enzyme inhibitors. In: Kinins-III, Part B, H Fritz, N Back, G Dietze, GL Haberland, eds. New York: Plenum Press, 1983, pp. 1127-1131.
273. Chobanian AV, Gavras H: Hypertensive emergencies. In: Medical emergencies diagnostic and management procedures from the Boston City Hospital, AS Cohen, JR Combes, HK Koh, eds. Boston: Little Brown and Company, 2nd edition, 1983, pp 105-114.
274. Hatzinikolaou P, Charocopoulos F, Gavras I, Gavras H: Systemic and regional hemodynamic effects of propranolol in intact and anephric rats. *Clin Exper Hyper Theory and Practice* A5(5):729-739, 1983.
275. Waeber B, Gavras H, Bresnahan M, Gavras I, Brunner HR: Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats. *Clin Sci* 65:255-261, 1983.
276. Tiffet CP, Gavras I, Melby JC, Gavras H, Chobanian AV: Urine Na/K humoral characteristics and blood pressure in essential hypertension. *Circulation* 68 (Suppl 3):90, 1983 (Abstract).
277. Gavras I, Gavras H: Captopril and enalapril. *Ann Int Med* 99:281, 1983 (Reply to letter).
278. Bussien JP, Waeber B, Nussberger J, Schaller MD, Gavras H, Hofbauer K, Brunner HR: Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? *Am J Physiol* 246:H143-H147, 1984.

279. Creager MA, Faxon DP, Rockwell SM, Melby JC, Gavras H, Coffman JD: Effect of renin-angiotensin system on limb circulation in normal subjects. *Am J Physiol* 246:H239-H244, 1984.
280. Dipette D, Gavras I, North WG, Dipette P, Gavras H: Vasopressin response to hyperosmotic stimulus: blood pressure effect in normal subjects and patients with impaired sympathetic system. *Clin Exper Hyper A6(4):851-861*, 1984.
281. Gavras I, Vlahakos D, Melby JC, Gavras H: Effects of the angiotensin converting enzyme inhibitor CI-906 on patients with essential hypertension. *Clin Res* 32:480A, 1984 (Abstract).
282. Kohlmann O Jr, Gavras H, Biollaz J, Biollaz B, Gavras I: Sodium-induced partial inhibition in vivo of  $\alpha_2$ -adrenoceptor agonist effect. *Clin Res* 32:502A, 1984 (Abstract).
283. Gavras H, Ribeiro AB, Kohlmann O, Saragoca M, Mulinari RA, Ramos O, Gavras I: Effects of a specific inhibitor of the vascular action of vasopressin in humans. *Hypertension* 6(Suppl 1): 156-160, 1984.
284. Kohlmann O Jr, Bresnahan M, Gavras H: Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats. *Hypertension* 6(Suppl 1):1-6, 1984.
285. Hatzinikolaou P, Gavras H, North WG, Kohlmann O, Gavras I: Evidence for dopaminergic regulation of vasopressin release in the anephric rat. *J Hypertension* 2:311-315, 1984.
286. Madias JD, Madias NE, Gavras H: Nonarrhythmogenicity of diuretic-induced hypokalemia: its evidence in patients with uncomplicated hypertension. *Arch Int Med* 144:2171-2176, 1984.
287. Charocopos F, Hatzinikolaou P, Gavras I, Gavras H: Regional blood flow and cardiac hemodynamics in renovascular and mineralocorticoid hypertensive rats. *J Physiol* 79:162-165, 1984.
288. Biollaz B, Biollaz J, Kohlmann O Jr, Bresnahan M, Gavras I, Gavras H: Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized deoxycorticosterone-salt hypertensive rats. *Eur J Pharmacol* 102:515-519, 1984.
289. Gavras I, Vlahakos D, Melby JC, Gavras H: Pilot study of the effect of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. *J Clin Pharmacol* 24:343-350, 1984.
290. Ying CY, Tiffit CP, Gavras H, Chobanian AV: Renal revascularization in the azotemic hypertensive patient resistant to therapy. *New Engl J Med* 311:1070-1075, 1984.
291. Charocopos F, Gavras H: Cardiovascular responses in the diabetic rat. *Q J Exp Physiol* 69:463-468, 1984.
292. Madias JE, Madias NE, Gavras HP: Diuretic-induced hypokalemia does not cause arrhythmias in patients with uncomplicated hypertension. *Clin Res* 32:676A, 1984 (Abstract).
293. Kohlmann O Jr, Gavras I, Biollaz J, Biollaz B, Gavras H: Sodium-induced attenuation in vivo of  $\alpha_2$  -adrenoceptor agonist function. *Hypertension* 6:786, 1984 (Abstract).
294. Gavras H, Gavras I: Managing hypertensives with parenchymal renal disease. *Cardiovasc Med* 10(2):43-54, 1985.

295. Charocopos F, Gavras H: Cardiovascular effects of dobutamine and converting enzyme inhibition in rats with diabetic ketoacidosis. *Pharmacology* 30:65-70, 1985.
296. Gavras H, Bain GT, Bland L, Vlahakos D, Gavras I: Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. *Brain Res* 343:113-119, 1985.
297. Kohlmann O Jr, Gavras I, Biollaz J, Biollaz B, Gavras H: Sodium chloride-induced partial inhibition in vivo of alpha2-adrenoceptor agonist function. *J Hypertension* 3:269-274, 1985.
298. Gavras H, Gavras I: Interaction of vasopressin with the sympathetic nervous system and arterial pressure and control. In: Vasopressin, Robert W Schrier, ed. New York: Raven Press, 1985.
299. Creager MA, Faxon DP, Cutler SS, Ryan TJ, Gavras H: The contribution of vasopressin to vasoconstriction in congestive heart failure. *J Am Coll Cardiol* 5:460, 1985 (Abstract).
300. Strauss R, Vlahakos D, Gavras I, Gavras H: Tolerability and efficacy MK-422 (enalaprilat) in hypertensive emergencies. *Clin Res* 33:289A, 1985 (Abstract).
301. Bresnahan MR, Hatinoglaou S, Muller RE, Gavras I, Gavras H: Central alpha<sub>1</sub>-adrenoceptors in spontaneously hypertensive, control and subtotaly nephrectomized rats on high or low salt diet. *Clin Res* 33:552A, 1985 (Abstract).
302. Gavras I, Hatinoglaou S, Gavras H: Calcium stimulates vasopressin release. *Clin Res* 33:554A, 1985 (Abstract).
303. Vlahakos D, Gavras I, Gavras H: Alpha adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. *Brain Res* 347:372-375, 1985.
304. Gavras I, Gavras H: Nifedipine in the treatment of essential hypertension. *J Clin Pharmacol* 25:429-432, 1985.
305. Creager MA, Faxon DP, Rockwell SM, Gavras H, Coffman JD: The contribution of the renin-angiotensin system to limb vasoregulation in patients with heart failure: observations during orthostasis and alpha-adrenergic blockade. *Clin Sci* 68:659-667, 1985.
306. Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, Faxon DP, Creager M, Gavras HP, Fouad FM, et al.: A cooperative multicenter study of captopril in congestive heart failure: Hemodynamic effects and long-term response. *Am Heart J* 110:439, 1985.
307. Fahmy NR, Gavras HP: Impact of captopril on hemodynamic and hormonal effects of nitroprusside. *J Cardiovasc Pharmacol* 7:869-874, 1985.
308. Gavras H, Gavras I: Risk of stroke in the hypertensive elderly patient. *Geriatric Med Today* 4(11):72-75, 1985.
309. Strauss R, Gavras I, Vlahakos D, Gavras H: Enalaprilate in hypertensive emergencies. *J Clin Pharmacol* 26:39-43, 1986.
310. Creager MA, Faxon DP, Cutler SS, Kohlmann O Jr, Ryan TJ, Gavras H: Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison of vasopressin to the renin-angiotensin system and the sympathetic nervous system. *J Am Coll Card* 7:758-765, 1986.



311. Ribeiro A, Mulinari R, Gavras I, Kohlmann O Jr, RAMOS O, Gavras H: Sequential elimination of pressor mechanisms in severe hypertension in humans. *Hypertension* 8(Suppl I):I-169-I-173, 1986.
312. Gavras H, Gavras I: Inhibitors of the renin-angiotensin system. In: Tratado Sobre Hipertension Arterial. JL Rodicio, et Madrid (1986).
313. Gavras H: How does salt raise blood pressure? a hypothesis. *Hypertension* 8:83-88, 1986.
314. Gavras I, Hatinoglou S, Gavras H: The adrenergic system and the release and pressor action of vasopressin. *Hypertension* 8(Suppl II):II-163-II-167, 1986.
315. Benetos A, Gavras I, Gavras H: Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. *Brain Res* 318:322-326, 1986.
316. Gavras I, Hatinoglou S, Benetos A, Gavras H: Calcium stimulates vasopressin release. *J Hypertens* 4:451-454, 1986.
317. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I: Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. *Hypertension* 8:971-974, 1986.
318. Benetos A, Gavras I, Gavras H: Hypertensive effect of a bradykinin antagonist in normotensive rats. *Hypertension* 8:1089-1092, 1986.
319. Gavras H, Benetos A, Gavras I: Bradykinin's contribution to normotension, shown by a competitive antagonist. *Hypertension* 8:832, 1986 (Abstract).
320. Young JC, Treadway JL, Balon TW, Gavras HP, Ruderman NB: Prior exercise potentiates the thermic effect of a carbohydrate load. *Metabolism* 35(11):1048-1053, 1986.
321. Gavras I, Gavras H: Clinical utility of angiotensin converting enzyme inhibitors in hypertension. *Am J Med* 81(4C):28-31, 1986.
322. Gavras H: A multicenter trial of enalapril in the treatment of essential hypertension. *Clin Ther* 9(Suppl I):24-38, 1986.
323. Bresnahan MR, Gavras I, Hatinoglou S, Muller RE, Gavras H: Central alpha-adrenoceptors during the development of hypertension in rats in high and low salt intake. *J Hypertens* 4:719-726, 1986.
324. Gavras H, Benetos A, Gavras I: Hypertensive effect of a bradykinin antagonist in normotensive rats. *Hypertension* 8:1089-1092, 1986.
325. Benetos A, Gavras I, Gavras H: Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. *Brain Res* 412:182-184, 1987.
326. Papadoliopoulou-Diamandopoulou N, Papagalanis N, Gavras I, Gavras H: Vasopressin in end-stage renal disease: Relationship to salt, catecholamines and renin activity. *Clin Exper Theory and Practice*, A9(7):1197-1208, 1987.
327. Mulinari RA, Saad CI, Kohlmann O Jr, Ribeiro AB, Gavras I, Gavras H: Cardiovascular role of vasopressin in the upright position in normotension and hypertension. Inter-American Society of Hypertension, Buenos Aires, Argentina, May 1987 (Abstract).
328. Ribeiro AB, Sadd CI, Zanella T, Mullinari RA, Kohlmann O Jr, Gavras H: Vasopressin maintains blood pressure in diabetic orthostatic hypotension. Inter-Am Soc Hypertens, Buenos Aires, Argentina, May 1987 (Abstract).

329. Gavras I, Gavras H: The role of angiotensin converting enzyme inhibitors in hypertension. In: The pharmacological treatment of cardiovascular diseases. Kostis JB, DeFelice EA, eds. MEPC, Alan Liss Inc, New York, 1987, pp. 93-122.
330. Mulinari RA, Benetos A, Gavras I, Gavras H: Interaction of bradykinin with catecholamines in blood pressure regulation. *Hypertension* 10:374, 1987 (Abstract).
331. Gavras I, Gavras H: Manejo clinico de la hipertension en el anciano. *Revista Clinica Espanola*. Vol 180, Num 5:229-231, 1987.
332. Gavras I, Gavras H: Clinical management of hypertension in the elderly. In: *Hypertension in the Community*, Eds T Rosenthal, D Silderberg, Karger Publ pp. 62-67, 1987.
333. Gavras H, Benetos A, Gavras I: Contribution of bradykinin to maintenance of normal blood pressure. *Hypertension* 9(Suppl III): III-147-III-149, 1987.
334. Mulinari R, Gavras I, Gavras H: Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. *Clin Ther* 9:678-692, 1987.
335. Benetos A, Bresnahan M, Gavras I, Gavras H: Central catecholamines and alpha-adrenoceptors in acute hypertension induced by intra-cerebroventricular hypertonic saline. *J Hypertens* 5:699-704, 1987.
336. Schneider SH, Khachadurian AK, Amorosa LF, Gavras H, Fineberg SE, Ruderman NB: Abnormal glucoregulation during exercise in type II (non-insulin-dependent) diabetes. *Metabolism* 36:1161-1166, 1987.
337. Gavras I, Mulinari R, Gavras H, Higgins JT, Reeves RL, Zawada ET, Crook J, Halperin AK, Garrett B: Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. *Am J Med* 83 (Suppl 6B):20-23, 1987.
338. Gavras H, Gavras I: Angiotensin converting enzyme inhibitors: Properties and side-effects. *Hypertension* 11(Suppl II):II-37-II-41, 1988.
339. Saad CI, Ribeiro AB, Zanella MT, Mulinari RA, Gavras I, Gavras H: The role of vasopressin in blood pressure maintenance in diabetic orthostatic hypotension. *Hypertension* 11(Suppl 1):I-217-I-221, 1988.
340. Mulinari R, Benetos A, Gavras I, Gavras H: Vascular and Sympathoadrenal Responses to Bradykinin and a Bradykinin Analogue. *Hypertension* 11:754-757, 1988.
341. Gavras I, Gavras H: Role of bradykinin in hypertension and the anti-hypertensive effect of angiotensin-converting enzyme inhibitors. *Am J Med Sci* 295:305-307, 1988.
342. Gavras I, Mulinari R, Gavras H: Renin-angiotensin and vasopressin in the development of salt-induced hypertension. *J Hypertens* 6:999-1002, 1988.
343. Gavras I, Mulinari R, Ribeiro A, Gavras H: Role of vasopressin in hypertension and heart failure: Clinical Studies In: Vasopressin : Cellular and Integrative Functions. Cowley AW, ed. Raven Press, New York, 467-479, 1988.
344. Makrides SC, Mulinari R, Zannis VI, Gavras H: Regulation of renin gene expression in hypertensive rats. *Hypertension* 12:405-410, 1988.
345. Gavras I, Gavras H: Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. *Kidney Int* 34(Suppl 26):60-62, 1988.

346. Mulinari RA, Gouni I, Gavras I, Gavras H: Acute effects of the new angiotensin-converting enzyme inhibitor cilazapril: a pilot study. *J Clin Pharmacol* 28:660-663, 1988.
347. Vlahakos D, Gavras H: Central sympathetic stimulation produced by saline application into the nucleus tractus solitarii area of conscious rats. *Neuroscience Letters* 92:335-340, 1988.
348. Gavras I, Bursztyn M, Gavras H: Changing trends in hypertension therapy: ACE inhibitors and calcium blockers. *Mod Medicine* 56:106-117, 1988.
349. Gavras H: Effects of sodium on central A<sub>2</sub> adrenergic receptors. *Hypertension* 12:525-526, 1988.
350. Bursztyn M, Gavras I, Boger R, Luther R, Glassman H, Gavras H: Dissociation between plasma renin inhibition and blood pressure response to a renin inhibitor in hypertensive patients. *Hypertension* 12(3):341, 1988 (Abstract).
351. Mulinari RA, Gavras I, Gavras H: Interaction of a bradykinin antagonist with prostaglandins in blood pressure regulation. *Hypertension* 12 (3):361, 1988 (Abstract).
352. Paglin S, Takuwa Y, Kamm K, Stull JT, Gavras H, Rasmussen H: Atrial natriuretic peptide inhibits the agonist-induced increase in extent of myosin light chain phosphorylation in aortic smooth muscle. *J Bio Chem* 263(26):13117-13120, 1988.
353. Gavras H: The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. *N Engl J Med* 319:1541-1543, 1988.
354. Glazier JJ, Gavras H, Mills RM, Ruocco NA, Bresnahan M, Ryan TJ, Faxon DP: Effect of arginine vasopressin on coronary hemodynamics. Presented at the 61st Scientific Session of the American Heart Association, Washington, DC, November 1988. (Abstract).
355. Gavras I, Gavras H: Enalapril. In: Drugs for the Heart and Circulation. FH Messerli, ed. WB Saunders Co., pp 792-799, 1990.
356. Mulinari R, Gavras I, Gavras H: The role of vasopressin in blood pressure regulation. In: Perspectives in Hypertension: II Endocrine mechanisms of Hypertension. Brenner BM, Kaplan N, and Laragh JH, eds. Raven Press, New York, 201-218, 1989.
357. Gavras I, Gavras H: Role of vasopressin in hypertensive disorders. In: Hypertension: Pathophysiology, Diagnosis and Management. Laragh JH and Brenner BM, eds. Raven Press, New York: 779-789, 1989.
358. Gavras H, Gavras I: Salt induced hypertension: The interactive role of vasopressin and of the sympathetic nervous system. *J Hypertens* 7:601-606, 1989.
359. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Platelet alpha<sub>2</sub>-receptor numbers diminish with age: Down regulation by Norepinephrine? *Clin Res* 37:(2) 531, 1989 (Abstract).
360. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Platelet alpha<sub>2</sub>-receptor affinity, plasma norepinephrine, norepinephrine and vasopressin in elderly black and white hypertensive patients. *Clin Res* 37: (2) 552, 1989. (Abstract).
361. Bursztyn M, Gavras I, Blasucci DJ, Gavras H: Intravenous Dilevalol in the treatment of severe hypertension. *J Cardiovasc Pharmacol* 13:799-802, 1989.
362. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Age dependent decrease of alpha<sub>2</sub>-receptor on human platelets. Presented at the American Geriatric Society, Boston, MA, May 1989 (Abstract).

363. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Differences in platelet alpha<sub>2</sub> receptor affinity, epinephrine and vasopressin levels in white and black elderly hypertensives vs normotensives. *Hypertension* 13:509, 1989 (Abstract).
364. Bursztyn M, Gavras I, Tiff CP, Bauer JH, Melby JC, Gavras H: Renin Inhibition: Effect on blood pressure and hormonal responses in man. Presented at the Fourth European Meeting on Hypertension, Milan, Italy, May 1989 (Abstract).
365. Mulinari R, Gavras I, Franco R, Gavras H: Bradykinin antagonism and prostaglandins in blood pressure regulation. *Hypertension* 13:960-963, 1989.
366. Glazier JJ, Faxon DP, Mills RM, Bresnahan MR, Ryan TJ, Gavras H: Effect of arginine vasopressin on coronary and systemic hemodynamics in man. *Int J Cardiol* 24:95-103, 1989.
367. Bursztyn M, Gavras I, Gavras H: Hypertension in the Aging Patients Implications for the Selection of Drug Therapy. *J Am Geriatr Soc* 37:814-818, 1989.
368. Lammek B, Wang YX, Derdowska I, Franco R, Gavras H: Synthesis and some pharmacologic properties of five novel V<sub>1</sub> or V<sub>1</sub>/V<sub>2</sub> antagonists of AVP. *Peptides* 10:1109-1112, 1989.
369. Bursztyn M, Gavras I, Gavras H: Quinapril: Mechanism of action, safety, and effectiveness. *Inter Med* 10:79-85, 1989.
370. Wallin JD, Cook ME, Fletcher E, Holtzman JI, Winer N, Gavras H, Grim CE, Ramanathan KB, Vidt DG, Johnson BF, Hall D, Stom M, Poland M, Cubbon J: Dilevalol in severe hypertension a multicenter trial of bolus intravenous dosing. *Arch Intern Med* 149:2655-2661, 1989.
371. Glazier JJ, Gavras H, Mills RM, Bresnahan M, Ryan TJ, Faxon DP: What is the effect of arginine vasopressin on coronary and systemic vascular tone in man? *Clin Sci* 77(Suppl 21):34P, 1989.
372. Bursztyn M, Gavras I, Tiff CP, Bauer JH, Melby JC, Gavras H: Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. *J Hypertens* 7:306-307, 1989.
373. Flordellis C, Castellano M, Zannis V, Gavras H: Tissue-specific expression of alpha<sub>2</sub>-adrenoceptor mRNA isoforms in rat. *Hypertension* 14:353, 1989.
374. Gavras H: Cardioprotective effects of angiotensin-converting-enzyme inhibitors in hypertension. *Practical Cardiology* 15:25-31, 1989.
375. Bursztyn M, Gavras I, Tiff CP, Luther R, Boger R, Gavras H: Effects of a novel renin inhibitor in patients with essential hypertension. *J Cardiovasc Pharmacol*: 15:493-500, 1990.
376. Mulinari RA, Gavras I, Wang YX, Franco R, Gavras H: Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. *Circulation* 81:308-311, 1990.
377. Gavras H: Angiotensin converting enzyme inhibition and its impact on cardiovascular disease. *Circulation* 81:381-388, 1990.
378. Gavras I, Gavras H: Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. In: *Adv Intern Med*, Year Book Medical Publishers, Inc. 35:249-267, 1990.

379. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Pressor Hormones in Elderly Hypertensive Persons Racial Difference. *Hypertension* 15:(Suppl I) I-88-I-92, 1990.
380. Wang YX, Franco R, Gavras I, Gavras H: Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and anti-antidiuretic activities in rats with left ventricular dysfunction. *Clin Res* 38:583A, 1990.
381. Gavras H: Angiotensin-Converting Enzyme Inhibitors or Calcium Channel Blockers? An Overview. *Drugs* 39 (Suppl 2)73-75,1990.
382. Flordellis C, Castellano M, Franco R, Zannis VI, Gavras H: Expression of multiple alpha<sub>2</sub>-adrenergic receptor messenger RNA species in rat tissues. *Hypertension* 15:881-887, 1990.
383. Bresnahan MR, Flordellis CS, Vassilatis DK, Makrides SC, Zannis VI, Gavras H: High level of expression of functional human platelet alpha<sub>2</sub>-adrenergic receptors in a stable mouse C127 cell line. *Biochemica et Biophysica Acta* 1052:439-445, 1990.
384. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Effect of Aging on Vasopressin, Catecholamines, and Alpha<sub>2</sub> -Adrenergic Receptors. *Amer Geriatr Soc* 38:628-632, 1990.
385. Gavras I, Gavras H: Enalapril. In: Cardiovascular Drug Therapy. Messerli F, ed. WB Saunders Co. Philadelphia, PA 1990 pp. 792-799.
386. Wang Y-X, Lammek B, Bresnahan M, Gavras I, Gavras H: Systemic and regional hemodynamic effects of bradykinin antagonist in normal conscious rats. *J Hypertens* 8 (Suppl 3):S3 (Abstract), 1990.
387. Lammek B, Wang Y-X, Gavras I, Gavras H: A new highly potent antagonist of bradykinin. *Peptides* 11:1041-1043, 1990.
388. Gavras H: Pressor systems in hypertension and congestive heart failure: Role of vasopressin. *Hypertension* 16:587-593, 1990.
389. Waeber B, Niederberger M, Gavras H, Nussberger J, Brunner HR: Hemodynamic effects of a kinin antagonist. *J Cardiovasc Pharmacol* 15 (Suppl 6):S78-S82, 1990.
390. Gavras H, Gavras I: Effects of bradykinin antagonists on the cardiovascular system. In: Bradykinin Antagonists Basic & Clinical Research. Burch RM, ed. Marcel Dekker, New York pp 171-189, 1991.
391. Gavras I, Gavras H: The future of converting enzyme inhibitors as cardioprotective agents. *Curr Opin in Cardiol* 5:626-629, 1990.
392. Franco RJS, Wang Y-Z, Mulinari R, Bresnahan M, Gavras I, Gavras H: Vasopressor role of endogenous bradykinin (BK) in renovascular hypertensive rats chronically treated with converting enzyme inhibitor ramipril. XIth International Congress of Nephrology Abstract, Tokyo, Japan 7/15-20/90.
393. Wang Y-X, Franco R, Gavras I, Gavras H: Effects of chronic administration of vasopressin antagonist with combined anti-vasopressor and anti-antidiuretic activities in rats with left ventricular dysfunction. *Clin Res* 38:583A, 1990 (Abstract).
394. Handy DE, Xia W, Flordellis C, Zannis V, Gavras H: Promoter region of the human platelet alpha-2 adrenergic receptor gene. *Hypertension* 16(3):338, 1990 (Abstract).
395. Flordellis C, Handy DE, Bresnahan M, Zannis V, Gavras H: Cloning and expression of a rat brain alpha-2B adrenergic receptor subtype. *Circulation* 82(4):233, 1990 (Abstract).

396. Wierzba T, Manolis A, Gavras I, Bursztyn M, Gavras H: Enalapril in mild to moderate hypertension. *Curr Ther Res* 48 (6):1101-1110, 1990.
397. Lammek B, Wang Y-X, Franco R, Gavras I, Gavras H: Two highly effective V<sub>2</sub>/V<sub>2</sub> antagonists of vasopressin containing novel thioacids at position 1. *J Pharm Pharmacol* 43:40-42, 1991.
398. Flordellis CS, Handy DE, Bresnahan MR, Zannis VI, Gavras H: Cloning and expression of a rat brain alpha2B-adrenergic receptor. *Proc Natl Acad Sci, USA* 88:1019-1023, 1991.
399. Wang Y-X, Gavras I, Wierzba T, Gavras H: Effects of N<sup>G</sup>-methyl-L-arginine on systemic and regional hemodynamics in conscious normal rats: relationship with bradykinin and prostaglandins. *Hypertension* 17:428, 1991 (Abstract).
400. Gavras I, Wang Y-X, Lammek B, Gavras H: Systemic and regional hemodynamic effects of indomethacin and its relationship with endogenous bradykinin in conscious normotensive rats. *Hypertension* 17:428, 1991 (Abstract).
401. Kohlmann O Jr, Spritzer N, Ribeiro AB, Plavnick FL, Ramos OL, Gavras H: Vasopressin and upright blood pressure control in essential hypertension: Influence of parasympathetic nervous system function. *Hypertension* 17:461, 1991 (Abstract).
402. DE Paula RB, Ribeiro AB, Kohlmann O Jr, Rodriguez CIS, Plavnick FL, Marson O, Ramos OL, Gavras H: Age and ethnicity modifies vasopressin participation in upright blood pressure control in essential hypertension. *Hypertension* 17:463, 1991 (Abstract).
403. Manolis A, Athansopoulos G, Karatasakis G, Gavras I, Cokkinos DV, Gavras H: Pressor hormone profile during stress in hypertension with or without left ventricular hypertrophy. *Amer J Hypertens* 4:50A, 1991 (Abstract).
404. Wang Y-X, Franco R, Gavras I, Gavras H: Effects of chronic administration of a vasopressin antagonist with combined anti- vasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. *J Lab Clin Med* 117:313-318, 1991.
405. Wang Y-X, Gavras I, Lammek B, Bresnahan M, Gavras H: Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. *J Hypertens* 9:805-812, 1991.
406. Gavras I, Gavras H: Cardioprotective potential of angiotensin-converting enzyme inhibitors. *Clin Cardiol* 14 (Suppl IV):68-71, 1991.
407. Gavras H: Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. *J KAU: Med Sci* 1:3-8 (1411 A.H./1991 A.D.).
408. Bakris GL, Gavras H: Treatment of hypertension in the elderly: a review. *Geriatr Nephrol & Urol* 1:121-127, 1991.
409. Gavras H: Role of vasopressin in clinical hypertension and congestive cardiac failure: Interaction with the sympathetic nervous system. *Clin Chem* 37:1828-1830, 1991.
410. Handy DE, Gavras H: Cis regulatory regions of the human alpha 2A adrenergic receptor gene. *Circulation* 84(4):II-337, 1991 (Abstract).
411. Gavras H, Gavras I: Angiotensin converting enzyme inhibitors: *J Hypertens* 9:1075, 1991 (Letter to editor).
412. Lammek B, Wang Y-X, Gavras I, Gavras H: A Novel bradykinin antagonist with improved properties. *J Pharm Pharmacol* 43:887-888, 1991.

413. Castellano M, Handy DE, Beschi M, Wang Y-X, Agabiti-Rosei E, Gavras H: Gene expression of catecholaminergic receptors in the central nervous system of hypertensive rats. *J Hypertens* 9(suppl 6):S54-S55, 1991.
414. Bakris GL, Bursztyn M, Gavras I, Bresnahan M, Gavras H: Pressor role of vasopressin in black hypertensives. *Hypertension* 18:378, 1991 (Abstract).
415. Lammek B, Wang Y-X, Gavras H: Synthesis and some pharmacologic properties of three new bradykinin antagonists. *Coll Czech Chem Comm* 56:1539-1544, 1991.
416. Bursztyn M, Gavras H: Clinical aspects of oral angiotensin converting enzyme inhibitors. In: *Progress in Hypertension* 2:107-129. H Saito, M Minami, SH Parvez, eds. The Netherlands, VSP BV, 1991.
417. Lammek B, Ito Y, Gavras I, Gavras H: Acylation of the N-terminus of B<sub>2</sub> bradykinin antagonists with bulky substituents dramatically increases potency. *Collect Czech Chem Commun* 57:1960-1966, 1992.
418. Gavras H: Early experience with quinapril in the management of hypertension. *Cardiovasc Rev & Rep* 13:55-57, 1992.
419. Gavras H, Gavras I: How ACE inhibition lowers blood pressure. *Choices in Cardiol* 6 (suppl 1) 15-17, 1992.
420. Wang Y-X, Gavras I, Wierzba T, Lammek B, Gavras H: Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. *Hypertension* 19 (suppl II):255-261, 1992.
421. Wang Y-X, Gavras I, Wierzba T, Gavras H: Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin-II receptor antagonist, and an angiotensin-converting enzyme inhibitor. *J Lab Clin Med* 119:267-272, 1992.
422. Gavras H: Oral Milrinone in Severe Chronic Heart Failure. *N Engl J Med* 326:1565, 1992 (Letter to editor).
423. Gavras H: The role of angiotensin converting enzyme inhibitors in the management of urgent hypertensive situations: A review. *Cardiovas Drug Rev* 10:117-124, 1992.
424. Bresnahan MR, Handy DE, Bogdanova NN, Gavras H: Regional differences in rat kidney  $\alpha_2$ -Adrenergic Receptor Subtypes. *Hypertension* 20:413, 1992 (Abstract).
425. Handy DE, Gavras H: Promoter region of the human alpha 2A adrenergic receptor gene. *J Biol Chem* 267:24017-24022, 1992.
426. Ruocco NA Jr, Yu T-K, Bergelson BA, Cannistra AJ, Cody C, Ryan TJ, Gavras H: Augmentation of coronary blood flow by ACE inhibition enhanced by endogenous bradykinin but not by angiotensin II receptor blockade. *Circulation* 86 (Suppl I):640, 1992 (Abstract).
427. Handy DE, Bogdanova NN, Bresnahan MR, Gavras H: Tissue Specific Distribution of Rat Alpha 2 Adrenergic Receptor Gene Transcripts. *Circulation* 86 (Suppl I):600, 1992 (Abstract).
428. Lammek B, Konieczna E, Wierzba T, Wang YX, Gavras H: Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminals. *Pol J Pharmacol Pharm* 44:179-186, 1992.
429. Gavras H, Gavras I: Hypertension in the elderly: Choosing the right therapy. *J Crit Illness* 7:1862-1874, 1992.

430. Gavras I, Gavras H: Angiotensin II -- Possible adverse effects on arteries, heart, brain, and kidney: Experimental, clinical, and epidemiological evidence. In: The Renin-Angiotensin System, Biochemistry Physiology Vol 1, JIS Robertson, MG Nicholls, eds. Gower Medical Publishing, London, pp. 40.1-40.11, 1993.
431. Bakris GL, Gavras H: Renin in acute and chronic renal failure: implications for treatment. In: The Renin-Angiotensin System, Pathophysiology Therapeutics, Vol 2, JIS Robertson, MG Nicholls, eds. Gower Medical Publishing, London, pp. 56.1-56.14, 1993.
432. Gavras I, Gavras H: Does bradykinin contribute to the actions of angiotensin converting enzyme inhibitors? In: Ace Report 95, MG Nicholls, ed. Current Science Ltd., pp. 1-8, 1993.
433. Sambhi MP, Gavras H, Robertson JIS, Smith WM: Long-range safety and protective benefits for angiotensin-converting enzyme inhibitors for hypertension--Do we need more clinical trials? *West J Med* 158:286-294, 1993 (Conferences and Reviews).
434. Gut A, Franco R, Ferrari-Spadotto A, Georgette J, Gavras I, Gavras H: Mechanisms of blood pressure maintenance in adriamycin induced nephropathy in rats: Role of vasopressin and angiotensin II. *Hypertension* 21:532-533, 1993 (Abstract).
435. Kohlmann O Jr, Ginoza M, Tavares A, Ribeiro AB, Gavras I, Gavras H: Bradykinin but not prostaglandins inhibition diminishes glucose uptake in Normotensive Wistar rats. *Hypertension* 21:540, 1993 (Abstract).
436. Oliveira JMF, Ribeiro AB, Gavras H, Saragoca MA, Mulinari RA: Vasopressin mediates vasoconstriction of chronic cyclosporine therapy. *Hypertension* 21:550, 1993 (Abstract).
437. Franco R, Salgado M, Ferrari-Spadotto A, Fabio S, Gavras I, Gavras H: Role of Bradykinin in the chronic antihypertensive effect of ramipril in rats with renovascular hypertension. *Hypertension* 21:556, 1993 (Abstract).
438. Huch KM, Wall BM, Bobal MA, Gavras H, CR Cook E: Blood pressure lowering effect of vasopressin during V1 Receptor Blockade. *Clin Res* 41:288A, 1993 (Abstract).
439. Manolis A, Athanasopoulos G, Karatasakis G, Gavras I, Bresnahan M, Cokkinos DV, Gavras H: Pressure hormone profile during stress in hypertension - Does vasopressin interfere with left ventricular hypertrophy? *Clin and Exper Hypertens* 15:539-555, 1993.
440. Handy DE, Flordellis CS, Bogdanova NN, Bresnahan MR, Gavras H: Diverse tissue expression of rat  $\alpha_2$ -adrenergic receptor genes. *Hypertension* 21:861-865, 1993.
441. Gavras H: ACE inhibitors and myocardial infarction. *Lancet* 341: 493, 1993 (Letter to Editor).
442. De Paula RB, Plavnik FL, Rodrigues CIS, De Assis Rocha Neves F, Kohlmann O Jr, Ribeiro AB, Gavras I, Gavras H: Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension. *Am J Hypertens* 6:794-798, 1993.
443. Gavras I, Gavras H: ACE Inhibitors: A decade of clinical experience. *Hospital Practice* 28:117-127, 1993.
444. Franco R, Gut A, Ferrari-Spadotto A, Georgette J, Gavras I, Gavras H: Mechanisms of blood pressure maintenance in adriamycin induced nephropathy in rats: Role of vasopressin and angiotensin II. XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993 (Abstract).



445. Franco R, Ferrari-Spadotto A, Georgette J, Fabio S, Cordellini S, Gavras I, Gavras H: Adriamycin induced nephropathy in rats: Role of renin angiotensin system in blood pressure control. XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993 (Abstract).
446. Franco R, Ferrari-Spadotto A, Fabio S, Gavras I, Gavras H: Role of bradykinin in the chronic antihypertensive effect of ramipril in rats with renovascular hypertension. XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993 (Abstract).
447. Gavras H: Pathophysiology of hypertension in the elderly. XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993 (Abstract).
448. Gavras H, Gavras I: Hypertension in the elderly: Pathophysiology of aging of the cardiovascular system. In: Nephrology and Urology in the Aged patient. DG Oreopoulos, MF Michelis, S Herschorn, eds. Kluwer Academic Publishers, 1993, pp. 141-145.
449. De Paula RB, Plavnik FL, Rodrigues CIS, De Assis Rocha Neves F, Kohlmann O Jr, Ribeiro AB, Gavras I, Gavras H: Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. *Ann NY Acad Sci* 689:534-536, 1993.
450. Franco R, Gut A, Ferrari-Spadotto A, Georgette J, Gavras I, Gavras H: Pressor Mechanisms in adriamycin-induced nephropathy with hypertension in rats. *Hypertension* 23:I-246-I-249, 1994.
451. Gavras H, Gavras I: On the JNC V Report. A Different Point of View. *Am J Hypertens* 7:288-293, 1994.
452. Gavras H: Angiotensin-converting enzyme (ACE) Inhibition: Dual Action on Hypertension and Cardiovascular Disease. *Am J Hypertens* 7:4A, 1994 (Abstract).
453. Handy DE, Zanella MT, Tavares A, Kanemaru A, Gavras H: Transcription regulation of the rat alpha 2A-adrenergic receptor gene. *Am J Hypertens* 7:9A, 1994 (Abstract).
454. Gavras H: Angiotensin-converting enzyme inhibition and the heart. *Hypertension* 23:813-818, 1994.
455. Bursztyn M, Gavras I, Gourley L, Desilva J, Whalen J, Gavras H: Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. *Clin Ther* 16:429-436, 1994.
456. Tobian L, Brunner HR, Cohn JN, Gavras H, Laragh JH, Materson BI, Weber MA: Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. *AJH* 7:859-872, 1994.
457. Tavares A, Handy DE, Bogdanova N, Rosene D, Gavras H: Detection of rat alpha2 adrenergic receptor ( $\alpha_2$ -AR) transcripts by in situ hybridization. *Hypertension* 24:413, 1994 (Abstract).
458. Huch KM, Wall BM, Mangold T, Bobal MA, Gavras H, CR Cooke: Hemodynamic effects of blockade of vasopressin V1 vascular receptors in dehydrated human subjects. *J Hypertens* 43(Suppl 1):64A, 1995 (Abstract).
459. Gavras I, Gavras H: Role of Vasopressin in Hypertensive Disorders: In: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. J.H. Laragh and B.M. Brenner, eds. Raven Press, Ltd., New York, pp 789-800, 1995.

460. Gavras H, Handy D, Gavras I: Alpha-adrenergic receptors in hypertension: In: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition. JH Laragh and BM Brenner, eds. Raven Press, Ltd., New York, pp 853-861, 1995.
461. Huch KM, Runyan KR, Wall BM, Gavras H, Cooke CR: Hemodynamic response to vasopressin during V<sub>1</sub>-receptor antagonism in baroreflex-deficient subjects. *Am J Physiol* 268: R156-R163, 1995.
462. Flordellis CS, Berguerand M, Gouache P, Barbu V, Gavras H, Handy DE, Bereziat G, Masliah J:  $\alpha_2$  adrenergic receptor subtypes expressed in Chinese hamster ovary cells activate differentially mitogen-activated protein kinase by a p21<sup>ras</sup> independent pathway. *J Biol Chem* 270:3491-3494, 1995.
463. Gavras H: What to anticipate from Ang II antagonists in the treatment of hypertension and chronic heart failure. *High Blood Pressure Research Council Newsletter* 3:20-21, 1995.
464. Kohlmann O, Jr, De Assis Rocha Neves F, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H: Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. *Hypertension* 25:1003-1007, 1995.
465. Gavras I, Manolis A, Gavras H: Effects of ACE inhibition on the heart. *J Hum Hypertens* 9:455-458, 1995.
466. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H: Reduction of sympathetic activity in the treatment of congestive heart failure. *Hypertension* 25:1368, 1995 (Abstract).
467. Kohlmann O Jr., Ginoza M, Cesaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H: Role for substance P in experimental hypertension. *Hypertension* 25: 1376, 1995 (Abstract).
468. Ruocco NA Jr, Bergelson BA, Yu T-K, Gavras I, Gavras H: Augmentation of Coronary Blood Flow by ACE Inhibition: Role of Angiotensin and Bradykinin. *Clin and Exper Hypertens* 17:1059-1072, 1995.
469. Handy, DE, Gavras H: Cell specific regulation of  $\alpha_{2A}$ -adrenergic receptor gene transcription. *Hypertension* 26:548, 1995 (Abstract).
470. Kohlmann O, JR., Ginoza M, Cesaretti ML, Zanella MT, Ribeiro AB, Leeman SE, Gavras I, Gavras H: Cardiovascular effects of a specific nonpeptide antagonist of substance P receptor in experimental hypertension. *Hypertension* 26:557, 1995 (Abstract).
471. Manolis A, Gavras I, Pieprzak M, Gavras H. Isradipine versus captopril in patients with essential hypertension. *Clin Ther* 17:648-655, 1995.
472. Gavras I, Gavras H: Bradykinin in hypertension and heart disease: effects of ACE inhibition. In: ACE Report 116. MG Nicholls, ed. Current Science, Ltd., pp 1-5, 1995.
473. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H: Suppressing sympathetic activation in congestive heart failure. *Hypertension* 26:719-724, 1995.
474. Haefliger J-A, Bergonzelli G, Waeber G, Aubert J-F, Nussberger J, Gavras H, Nicod P, Waeber B: Renin and Angiotensin II Receptor Gene Expression in Kidneys of Renal Hypertensive Rats. *Hypertension* 26:733-737, 1995.
475. Gavras H, Gavras I: Modern approaches to initiating antihypertensive therapy. *Cardiology Clinics* 13:593-598, 1995.

476. Handy DE, Zanella MT, Kanemaru A, Tavares A, Flordellis C, Gavras H: A negative regulatory element in the promoter region of the rat  $\alpha_2A$ -adrenergic receptor gene overlaps an SP1 consensus binding site. *Biochem J* 311:541-547, 1995.
477. Kohlmann O Jr., Ginoza M, Cesaretti ML, Zanella MT, Ribeiro AB, Tavares A, Ramos OL, Leeman SE, Gavras I, Gavras H: Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in DOCA-salt hypertension. *Hypertension* 26:(Part 2) 1186-1189, 1995.
478. Wall BM, Huch KM, Runyan KR, Williams HH, Gavras H, Cooke CR: Effects of vasopressin  $V_1$ -receptor blockade during acute and sustained hypovolemic hypotension. *Am J Physiol* 270: R356-R364, 1996.
479. Tavares A, Handy DE, Bogdanova NN, Rosene DL, Gavras H: Localization of  $\alpha_{2A}$ - and  $\alpha_{2B}$ -adrenergic receptor subtypes in Brain. *Hypertension* 27:449-455, 1996.
480. Handy DE, Gavras H: Evidence for cell-specific regulation of transcription of the rat  $\alpha_{2A}$ -adrenergic receptor gene. *Hypertension* 27:1018-1024, 1996.
481. Gavras H, Gavras I: Initiating antihypertensive therapy in the 1990s. In: *ACE Inhibition & Your Practice*. H. Ikram, ed., English Thornton Communications, Inc., pp 1-6, 1996.
482. Gavras I, Gavras H: Cardioprotective potential of angiotensin converting enzyme inhibitors. *Brazilian J Med Biol Res* 29:701-705, 1996.
483. Gavras H, Gavras I: Endothelial function in cardiovascular disease: the role of bradykinin. In: *Bradykinin*. Sara Black, ed., Science Press Limited, London, UK, pp 1-58, 1996.
484. Manolis AJ, Olympios C, Sifaki M, Handanis S, Foussas S, Bresnahan M, Gavras I, Gavras H: Effects of combined sympathetic suppression and angiotensin-converting enzyme (ACE) inhibition in congestive heart failure (CHF). *Hypertension* 28:510, 1996 (Abstract).
485. Kohlmann O, JR., Cesaretti ML, Ginoza M, Zanella MT, Ribeiro AB, Leeman SE, Gavras I, Gavras H: Influence of salt-dependency on the cardiovascular effects of a specific nonpeptide antagonist of substance P receptor in experimental hypertension. *Hypertension* 28:542, 1996 (Abstract).
486. Handy DE, Gavras H: Role of an E-box in regulating  $\alpha_{2A}$ -adrenergic receptor expression: *Hypertension* 28:543, 1996 (Abstract).
487. Bakris GL, Kusmirck SL, Smith AC, Gavras I, Gavras H: Calcium antagonists prevent reductions in arterial pressure mediated by vasopressin receptor antagonism. *Hypertension* 28:548, 1996. (Abstract).
488. Gavras I, Gavras H: What data are required to adopt new antihypertensive agents? *Am J Ther* 3:604-607, 1996.
489. Johns C, Gavras I, Handy DE, Salomao A, Gavras H: Models of experimental hypertension in mice. *Hypertension* 28:1064-1069, 1996.
490. Gavras H, Salerno CM: The angiotensin II type 1 receptor blocker losartan in clinical practice: A review. *Clin Ther* 18:1058-1067, 1996.
491. Gavras H: Contemporary choices for the treatment of hypertension. *Hellenic J Cardiol* 37:493-499, 1996 (Editorial).
492. Manolis A, Gavras I, Gavras H: Clonidine and heart failure. *Hypertension* 27: 1187-1188, 1996 (Letter to Editor).

493. Gavras I, Gavras H: Commentary on Kostis' Report From SOLVD. *Am J Hypertens* 9:615, 1996 (Letter to Editor).
494. Gavras H: Introduction. In: Postgraduate Medicine, A Special Report on Clinical Experience with Losartan, the first A-II blocker, in diverse hypertensive populations. Published by Healthcare Information Programs, McGraw-Hill Healthcare Information Group, Minneapolis, MN, pp 5&6, 1997.
495. Gavras H: Commentary: A hypertension report card. In: Postgraduate Medicine, A special Report on Clinical Experience with Losartan, the first A-II blocker, in diverse hypertensive populations. Published by Healthcare Information Programs, McGraw-Hill Healthcare Information Group, Minneapolis, MN, pp 7-12, 1997.
496. Kohlmann O Jr., Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, Ramos OL, Leeman SE, Gavras I, Gavras H: Role of Substance P in blood pressure regulation in salt-dependent experimental hypertension. *Hypertension* 29 (part 2): 506-509, 1997.
497. Manolis AJ, Olympios C, Sifaki M, Handanis S, Cokkinos D, Bresnahan M, Gavras I, Gavras H: Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. *Hypertension* 29 (part 2): 525-530, 1997.
498. Manolis AJ, Olympios C, Sifaki M, Handanis S, Argirakis S, Katsaros C, Gavras I, Gavras H: Chronic sympathetic suppression in the treatment of chronic congestive heart failure. *Hypertension* 29:939, 1997 (Abstract).
499. Manolis AJ, Beldekos D, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H: Hemodynamic and hormonal correlates in essential hypertension. *Hypertension* 29:861,1997 (Abstract).
500. Gavras I, Manolis AJ, Gavras H: Drug Therapy for Hypertension. *American Family Physician* 55:1823-1834,1997.
501. Gavras H: Mouse Models of Experimental Hypertension. *Am J Hypertens* 10:218A, 1997 (Abstract).
502. Gavras H: Prevention of Myocardial Damage in Hypertension. *Am J Hypertens* 10:237A, 1997 (Abstract).
503. Gavras H: Result of the U.S. Hyertension Report Card. *Am J Hypertens* 10:240A, 1997 (Abstract).
504. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H: Role of vasopressin in essential hypertension: racial differences. *J Hypertens* 15:545-550, 1997.
505. Manolis AJ, Beldekos D, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H: Hemodynamic and humoral correlates in essential hypertension. Relationship between patterns of LVH and myocardial ischemia. *Hypertension* 30 (part 2):730-734, 1997.
506. Handy DE, Johns C, Bresnahan M, Gavras H: Expression of  $\alpha_2$ -adrenergic receptor in Normal and Atherosclerotic Rabbit Aorta. *Hypertension* 30:507, 1997 (Abstract).
507. Bakris LG, Kusmirek SL, Smith AC, Gavras I, Gavras H: Calcium antagonism abolishes the antipressor action of vasopressin ( $V_1$ ) receptor antagonism. *Am J Hypertens* 10:1153-1158, 1997.

508. Gavras H: Angiotensin II antagonism: a new avenue of hypertension management. *Blood Pressure. (Suppl 1)* 6:42-46, 1997.
509. Gavras I, Gavras H: Potencial cardioprotector de los inhibidores del enzima conversor de la angiotensina. *Anales De Cirugia Cardiaca Y Cirugia Vasculat* 3:185-189,1997.
510. Gavras H, Chrysant SG, Niederman AL, Marbury TC, Goldstein R, Conradi E: Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension. *Clin Exper Hypertens* 20:41-52, 1998.
511. Gavras I, Gavras H: The calcium channel antagonist controversy. *Amer Fam Phys* 57:1484 &1492, 1998 (Editorial).
512. Gavras H, Gavras I: Hypertension in the Elderly. Hormonal and Therapeutic Aspects. In: Recent Advances in Geriatrics, editors: Mario Barbagallo, Giuseppe Licata, James R. Sowers. Plenum Press, New York, pp 69-74, 1998.
513. DeStefano, AL, Gavras H, Burzstyn M, Gavras I, Handy DE, Joost O, Nicolaou M, Streeten D, Schwartz F, Farrer LA, Baldwin CT: Localization of a gene for blood pressure regulation to human chromosome 18q. *Am J Hypertens* 11:5, 1998 (Abstract).
514. Gavras H, Gavras I: Efficacy of eprosartan in patients with essential hypertension: A 26-week comparison study of eprosartan versus enalapril. *Am J Hypertens* 11:79, 1998 (Abstract).
515. Gavras H: Role of the renin angiotensin system and the sympathetic nervous system in the heart. *Am J Hypertens* 11:244, 1998 (Abstract).
516. Gavras I, Gavras H: Salt in Hypertension: Physiological and Molecular Aspects. *Recent Progress in Hormone Research* 53: 1-6, 1998.
517. Monteagudo PT, Gavras H, Kohlmann O, Ribeiro AB, Zanella, MT: The influence of vascular vasopressin action on blood pressure profile in type I diabetics with severe autonomic neuropathy. *J Hypertens* 16(suppl 2): S144, 1998 (Abstract).
518. Manolis AJ, Beldekos D, Handanis S, Haralabidis G, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H: Comparison of spirapril, Isradipine, or combination in hypertensive patients with left ventricular hypertrophy. Effects on LVH regression and arrhythmogenic propensity. *Am J Hypertens* 11:640-648, 1998.
519. Handy DE, Johns C, Bresnahan MR, Tavares A, Bursztyn M, Gavras H: Expression of  $\alpha_2$ -adrenergic receptors in normal and atherosclerotic rabbit aorta. *Hypertension* 32:311-317, 1998.
520. Manolis AJ, Olympios C, Sifaki M, Smirnioudis N, Handanis S, Argirakis S, Katsaros C, Gavras I, Gavras H. Chronic sympathetic suppression in the treatment of chronic congestive heart failure. *Clin Exper Hypertension* 20:717-731, 1998.
521. Manolis AJ, Tsalopoulos E, Ramos C, Katsaros K, Dalabiras P, Hatzissavas J, Foussas S, Gavras I, Gavras H. Benefits of central sympathetic suppression with clonidine after acute myocardial infarction. *Circulation* 98 (suppl I):I-446, 1998 (Abstract).
522. Balbi, AL, Franco RJS, Barretti P, Gavras I, Gavras H. Renal artery clipping attenuates the progression of adriamycin nephropathy. *Am J Hypertens* 11:1124-1128, 1998.

523. Makaritsis KP, Gavras H, Du Y, Chobanian AV, Brecher P.  $\alpha_1$ -Adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. *Hypertension* 32:1044-1048, 1998.
524. Gavras H. Genetic Profiling in Hypertension. In: Hypertension Primer, Second Edition. Senior Editors: Joseph L. Izzo, Jr. and Henry R. Black. Lippincott Williams & Wilkins, Baltimore, MD, pp 306-307, 1998.
525. Gavras I, Gavras H. The renin-angiotensin system in hypertensive cardiac disease. In: Renin Angiotensin 74: 265-272, 1998. Editors: H.R. Ulfendahl, M. Aurell. Portland Press, London.
526. DeStefano AL, Baldwin CT, Burzstyn M, Gavras I, Handy DE, Joost O, Martel T, Nicolaou M, Schwartz F, Streeten DHP, Farrer LA, Gavras H. Autosomal dominant orthostatic hypotensive disorder maps to chromosome 18q. *Am J Hum Genet* 63:1425-1430, 1998.
527. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin angiotensin aldosterone system and safety parameters: results from a 26 week double-blind, multicenter study. *Curr Med Res Opinion* 15: 15-24, 1999.
528. Gavras H. Historical overview: blocking the renin-angiotensin system in heart failure. In: 100 years of the renin—angiotensin system. Eds.: M G. Nicholls, H. R. Brunner, H. Ikram, Charles S. Sweet and J. Findlay Walker. Published by Hughes Associates, Hooper House, Oxford, UK pp 43-45, 1998.
529. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the  $\alpha_{2B}$ -adrenergic receptor in the development of salt-induced hypertension. *Hypertension* 33:14-17, 1999.
530. Gavras I, Gavras H. Safety and tolerability of eprosartan. *Pharmacotherapy* 19 ( 4 Pt 2): 102S-107S, 1999.
531. Gavras H, Gavras I. Bioactive peptides in the treatment of hypertension and heart failure. In: Bioactive Peptides in Drug Discovery and Design: Medical Aspects. Eds.: J. Matsoukas, T. Mavromoustakos. Published by IOS Press, Amsterdam, Netherlands, pp 41-50, 1999.
532. Baima J, Nicolau M, Schwartz F, DeStefano A, Gavras I, Manolis A, Farrer L, Baldwin C, H Gavras. Evidence for linkage between essential hypertension and a putative locus on human chromosome 17 in Caucasian Americans. *Hypertension*:33:1066, 1999 (Abstract).
533. Monteagudo PT, Gavras H, Kohlman O, Jr. Ribeiro AB, Zanella MT. The effect of vasopressin blockade on 24-h blood pressure profile in diabetics with severe autonomic neuropathy. *Hypertension* 33:1085, 1999 (Abstract).
534. Elijovich F, Laffer CL, Schiffrin EL, Gavras H,. Co-stimulation of endothelin and catecholamines by low sodium in salt-sensitive hypertensive patients. *Hypertension* 33:1075, 1999 (Abstract).
535. Gavras H. Historical evolution of angiotensin II receptor blockers: Therapeutic advantages. *J Am Soc Nephrol* 10:S255-S257, 1999.
536. Gavras I, Manolis A, Gavras H. Genetic epidemiology of essential hypertension. *J Hum Hypertens* 13:225-229, 1999.
537. Gavras H, Gavras I. The renin-angiotensin system and the heart. In: Contemporary Endocrinology: Hormones and the Heart in Health and Disease. Ed.: L. Share. Published by Humana Press Inc., Totowa, NJ, pp 63-67, 1999.

538. Manolis AJ, Hatziloakim G, Pittaras A, Haralambidis G, Hatzigeorgiou S, Zairis M, Foussas S, Bresnahan M, Gavras I, Gavras H. Patterns of neurohormonal activation in cardiovascular diseases. *Eur J Hrt Failure (Suppl 1)* page 67, 1999 (Abstract).
539. Manolis AJ, Katsaros K, Pittaras A, Haralambidis G, Hatziloakim G, Psaras, Rammos C, Foussas S, Bresnahan M, Gavras I, Gavras H. Neurohormonal activation and heart rate variability in cardiovascular diseases (Presented at the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, Aug. 28-Sept. 1, 1999). *Eur Hrt J* 20:570, 1999 (Abstract).
540. Baima J, Nicolau M, Schwartz F, DeStefano A, Manolis A, Gavras I, Laffer C, Elijovich F, Farrer L, Baldwin C, H Gavras. Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. *Hypertension* 34: 4-7, 1999.
541. Makaritsis KP, Handy DE, Johns C, Altman J, Bresnahan M, Gavras I, Gavras H. Sympathoinhibitory function of the  $\alpha_2A$  adrenergic receptor subtype. *Hypertension* 34:330, 1999 (Abstract).
542. Manolis A, Dernellis J, Stefanadis C, Gavras I, Gavras H, Toutouzas P. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensives with diastolic heart dysfunction. *Hypertension* 34:332, 1999 (Abstract).
543. Paigen B, Fumihiko S, Churchill GA, Higgins D, Markaritsis K, Johns C, Gavras, H. Quantitative trait loci analysis of salt-induced blood pressure elevation in C57BL/6J and AJ mice. *Hypertension* 34:333, 1999 (Abstract).
544. Schwartz F, Baldwin CT, Baima J, Gavras H. Mitochondrial DNA mutations in patients with orthostatic hypotension. *Am J Med Genet* 86:145-150, 1999.
545. Makaritsis KP, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, Gavras H. Sympathoinhibitory function of the  $\alpha_2A$  adrenergic receptor subtype. *Hypertension* 34:403-407, 1999.
546. Baldwin, CT, Schwartz F, Baima J, Burzstyn, DeStefano AL, Gavras I, Handy DE, Joost O, Martel T, Manolis A, Nicolaou M, Bresnahan M, Farrer L, Gavras H. Identification of a Polymorphic Glutamic Acid Stretch in the  $\alpha_2$ -adrenergic receptor and lack of linkage with essential hypertension. *Am J Hypertens* 12:853-857, 1999.
547. Gavras I, Manolis AJ, Gavras H. The economics of therapeutic advances. The paradigm of sympathetic suppression in chronic heart failure. *Arch Intern Med* 159:2634-2636, 1999.
548. Gavras H, Gavras I. Commentary: Implications for the pathophysiology of hypertension and heart failure derived from clinical experience with drugs modifying the renin-angiotensin system. In *Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery*. Eds: A. Husain and R. M. Graham. Published by Harwood Academic Publishers, Amsterdam, The Netherlands pp 187-190, 2000.
549. Manolis AJ, Tsalopoulos E, Ramos C, Katsaros K, Dalabiras P, Hatzissavas J, Foussas S, Gavras I, M. Bresnahan, Gavras H. Benefits of central sympathetic suppression with clonidine after acute myocardial infarction. *Advances in Therapy* 16:272-282, 1999.
550. Gavras, H. Update on the clinical pharmacology of candesartan cilexetil. *Am J Hypertens* 13:25S-30S, 2000.

551. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of  $\alpha_2$ -adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. *Hypertension* 35:609-613, 2000.
552. Gavras I, Gavras H. The role of AII antagonists in hypertension: Focus on telmisartan. *Cardiovascular Reviews and Reports* 21: 76-80, 2000.
553. Nicolaou M DA, Gavras I, Cupples LA, Manolis A J, Baldwin CT, Gavras H, Farrer LA. Genetic predisposition to stroke in relatives of hypertensives. *Stroke* 31:487-492, 2000.
554. Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. *Biochim Biophys Acta* 1500:280-90, 2000.
555. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. *Am J Hypertens* 13:512-7, 2000.
556. Gavras H. Effect of Ramipril on cardiovascular events in high-risk patients. *N Engl J Med* 343:65-66, 2000 (Letter to the Editor).
557. Brunner HR, Gavras H. Early experience with angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors. In: Angiotensin II Receptor Antagonists. Eds.: M. Epstein, HR Brunner. Published by Hanley & Belfus, Inc., Philadelphia, PA, pp 79-87, 2000.
558. Gavras H, Gavras I. Cardiac effects of angiotensin II and AT<sub>1</sub> receptor blockade. In: Angiotensin II Receptor Antagonists. Eds.: M. Epstein, HR Brunner. Published by Hanley & Belfus, Inc., Philadelphia, PA, pp 215-222, 2000.
559. Duka I, Gavras I, Johns C, Handy DE, Gavras H. Role of the postsynaptic  $\alpha_2$ -adrenergic receptor subtypes in catecholamine-induced vasoconstriction *Gen Pharmacol: The Vascular System* 34:101-106, 2000.
560. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, Cupples A, Myers RH. Evidence of a Gene influencing blood pressure on chromosome 17: Genome scan linkage Results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. *Hypertension* 36:477-483, 2000.
561. DeStefano AL, Gavras H, Heard N, Bursztyrn M, Manolis A, Farrer LA, Baldwin CT, Gavras I, Schwartz F. Maternal influence on the inheritance of hypertension. *Hypertension* 36:718, 2000 (Abstract).
562. Duka I, Johns C, Gavras, I, Bresnahan MR, Gavras H. Role of the bradykinin B<sub>2</sub> receptor in salt-induced hypertension. *Hypertension* 36:727, 2000 (Abstract).
563. Gavras I, Gavras H. Angiotensin-converting enzyme inhibitors. In: Hypertension Medicine. Editor: Michael A. Weber, Published by Humana Press, Totowa, New Jersey, pp 315-324, 2000.
564. Laffer CL, Schiffrin EL, Gavras H, Elijovich F. Plasma endothelin of sibpairs: Variability, inheritance, and linkage to obesity in essential hypertension. *Hypertension* 36:725, 2000 (Abstract).
565. Elijovich F, Laffer CL, Amador E., Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. *Circulation* 103:263-268, 2001.



566. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the B<sub>1</sub> bradykinin receptor in normotension and hypertension. *Circ Res* 88:275-281, 2001.
567. Gavras H, Brunner HR. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. *Hypertension* 37:342-345, 2001.
568. Sugiyama F, Churchill GA, Higgins DC, Johns C, Makaritsis KP, Gavras H, Paigen, B. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. *Genomics* 71:70-77, 2001.
569. Manolis AJ, Psomali D, Pittaras A, Loukatzikou A, Beldekos D, Karagianni E, Foussas S, Bresnahan MR, Gavras I, Gavras H. Comparison of diltiazem-SR vs amlodipine on resting and stimulated blood pressure, catecholamines and diastolic dysfunction in patients with mild to moderate essential hypertension. *Am J Hypertens* 14:102A, 2001 (Abstract).
570. Gavras I, Gavras H. Role of  $\alpha_2$ -adrenergic receptors in Hypertension. *Am J Hypertens* 14:171S-177S, 2001.
571. Gavras H. Issues in hypertension: Drug tolerability and special populations. *Am J Hypertens* 14:231S-236S, 2001.
572. DeStefano AL, Gavras H, Heard-Costa N, Bursztyrn M, Manolis A, Farrer LA, Baldwin CT, Gavras I, Schwartz F. Maternal component in the familial aggregation of hypertension. *Clin Genet* 60:13-21, 2001.
573. Kintsurashvili E, Gavras I, Johns, C, Gavras, H. Effects of Antisense oligodeoxynucleotide targeting of the  $\alpha_{2B}$ -adrenergic receptor mRNA in the Central Nervous System. *Hypertension* 38:488, 2001 (Abstract).
574. Kintsurashvili E, Duka I, Johns, C, Gavras I, Gavras, H. Effects of angiotensin II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. *Hypertension* 38:500, 2001 (Abstract).
575. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras, H. Insulin sensitivity and the B<sub>2</sub> type receptor of bradykinin. *Hypertension* 38:508, 2001 (Abstract).
576. Kintsurashvili E, Duka I, Gavras I, Johns, C, Farmakiotis D, Gavras, H. Effects of Ang II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* 281:H1778-H1783, 2001.
577. Stefanadis C, Manolis A, Dernellis J, Tsioufis C, Tsiamis E, Gavras I, Gavras H, Toutouzias P. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensive patients with diastolic heart dysfunction. *J Hum Hypertens* 15:635-642, 2001.
578. Gavras I, Gavras H. Role of angiotensin-converting enzyme (ACE) in the pathophysiology of hypertension. In: Angiotensin-Converting Enzyme (ACE): Clinical and Experimental Insights. Editor: Thomas D. Giles, Published by Health Care Communications, Inc., Fort Lee, New Jersey, pp 123-126, 2001.
579. Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of Antisense oligodeoxynucleotide targeting of the  $\alpha_{2B}$ -adrenergic receptor messenger RNA in the central nervous system. *Hypertension* 38:1075-1080, 2001.

580. Manolis A, Pittaras A, Psomali D, Beldekos D, Argyrakis S, Handanis S, Karagianni E, Gavras I, Gavras H, Foussas S. Comparison of diltiazem versus amlodipine in blood pressure regulation at rest and during exercise, as well as catecholamine levels and diastolic dysfunction in mild to moderate essential hypertension. *Hellenic J Cardiol* 42 (Suppl): 46, 2001 (Abstract).
581. Malakos IS, Voudris B, Gatzov P, Avramides D, Skoularigis I, Manolis A, Kourgiannides G, Gavras I, Gavras H, Cokkinos DF. Effect of acute decrease in arterial pressure on coronary flow in angiographically normal coronary arteries. *Hellenic J Cardiol* 42 (Suppl): 290, 2001 (Abstract).
582. Gavras I, Manolis AJ, Gavras H. The alpha2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. *J Hypertens* 19:2115-2124, 2001.
583. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? *Curr Control Trials Cardiovasc Med* 2:257-259, 2001.
584. Gavras I, Gavras H. The role of ACE inhibition in heart failure. In: ACE Inhibitors, editors: Pedro D'Orleans-Juste, Gerard E. Plante. Published by Birkhauser Verlag, Basel, Switzerland, pp71-79, 2001.
585. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras, H. Role of the B<sub>2</sub> receptor of bradykinin in insulin sensitivity. *Hypertension* 38:1355-1360, 2001.
586. Monteagudo PT, Gavras H, Gavras I, Kohlmann O, Jr., Ribeiro AB, Zanella MT. Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. *Am J Hypertens* 15:42-47, 2002.
587. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. *The Lancet* 359:990-992, 2002.
588. Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Reversal of salt-induced hypertension by translational inhibition of the alpha2B-adrenergic receptor (AR). *AJH* 15: 156A, 2002 (Abstract).
589. Peters LL, Svenson KL, O'Brien TP, Barker JE, Bult CJ, Gavras H, Pack AI, Schwartz DA, Paigen BJ. Phenotype driven approaches to gene discovery: A large scale strain characterization and mutagenesis program to detect variation in heart, lung, blood, and sleep phenotypes in the mouse (NHLBI Program for Genomic Applications, PGA). *Blood* 98:10A, 2002 (Abstract).
590. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. *J Hum Hypertens* 16 (Suppl 2): S2-S6, 2002.
591. Gavras I, Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. *Current Opinion in Endocrinology & Diabetes* 9:323-328, 2002.
592. Gavras I, Gavras H. Angiotensin blockers in the treatment of hypertension. In: Harrison's Advances in Cardiology. Eugene Braunwald, ed., McGraw-Hill, pp 75-79, 2002.
593. Gavras H. Inappropriate attribution: The lazy author syndrome. *AJH* 15:831, 2002.
594. Duka I, Kintsurashvili E, Johns C, Gavras I, Gavras H. Vasodilatory effect of the B<sub>1</sub> receptor of bradykinin: Direct or autacoid-mediated? *Hypertension* 40:391, 2002 (Abstract).

595. Gavras, H. Gavras. Angiotensin-converting enzyme/kininase II: hemodynamic and metabolic effects. *Greek Nephrology* 14:445-448, 2002
596. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? *Arch Intern Med* 163:240-241, 2003.
597. Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Central alpha<sub>2B</sub>-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. *J Hypertens* 21:961-967, 2003.
598. Voudris V, Malakos J, Avramidis D, Gatzov,P, Skoularigis J, Cokkinos D, Manolis AJ, Gavras I, Gavras H. Effect of rapid blood pressure decreases on coronary flow reserve in normal coronary arteries. *Am J Hypertens* 16: 21A, 2003 (Abstract).
599. Sun F, Cui J, Gavras H, Schwartz F. A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases. *Am J Hum Genet* 72:1515-1526, 2003.
600. Erlich PM, Cui J, Chazaro I, Farrer LA, Baldwin CT, Gavras H, DeStefano AL: Genetic variants of WNK4 in whites and African Americans with hypertension. *Hypertension* 41:1191-1195, 2003.
601. Duka I, Duka A, Gavras, I, Bresnahan M, Gavras, H. Interaction of bradykinin with other vasoactive systems in blood pressure regulation. *Hypertension* 42: 420, 2003 (Abstract).
602. Cui, J, Zhou X, Chazaro I, DeStefano AL, Manolis AJ, Baldwin CT, Gavras H. Association of polymorphisms in the promoter Region of the PNMT gene with essential hypertension in African Americans ut not in Whites. *Am J Hypertens* 16:859-863, 2003.
603. Duka I, Duka A, Kintsurashvili E., Johns C, Gavras I, Gavras H. Mechanisms mediating the vasoactive effects of the B<sub>1</sub> receptors of bradykinin. *Hypertension* 42:1021-1025, 2003.
604. Voudris V, Avramides D, Gatzov P, Malakos J, Skoularigis J, Manolis A, Gavras, H, Gavras I, Cokkinos DV. The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. *Am J Hypertens* 16:1000-1005, 2003.
605. Schwartz F, Duka A, Triantafyllidi E, Johns C, Duka I, Cui J, Gavras H. Serial analysis of gene expression in mouse kidney following angiotensin II administration. *Physiol Genomics* 16:90-98, 2003.
606. Gavras, H. The discovery of captopril. *FASEB J* 18:225, 2004 (Letter to Editor).
607. Elijovich F, Laffer CL, Schiffrin E, Gavras H, Amador E. Endothelin-aldosterone interaction and proteinuria in low-renin hypertension. *J Hypertens* 22:573-582, 2004.
608. Triantafyllidi E, Baldwin C, Schwartz F, Gavras H. Study of hypertension in spontaneous hypertensive rats by sequencing the genomic DNA of alpha<sub>2B</sub> receptors. *Hellenic J Cardiol* 45:65-70, 2004.
609. Larkin JE, Frank BC , Gaspard RM, Duka I, Gavras H, Quackenbush J. Cardiac transcriptional response to acute and chronic angiotensin II treatments. *Physiol Genomics* 18:152-166, 2004.
610. Ignjacev I, Kintsurashvili E, Conrado J, Vitseva O, Shenouda S, Gavras I, Gavras H. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. *Am J Hypertens* 17:8A, 2004 (Abstract).

611. Di Petrillo K, Sheehan S, Melista E, Cui J, De Stefano A, Baldwin C, Gavras H, Churchill G, Paigen B. Novel Role for Podocin as a genetic cause of hypertension. *Am J Hypertens* 17:19A, 2004 (Abstract).
612. Gavras I, Gavras H. Hypertension, vasoactive peptides and coagulation factors. *J Hypertens* 22:1091-1092, 2004 (Editorial).
613. Schwartz F, Duka A, Sun F, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. *Amer J Hypertens* 17:629-635, 2004.
614. Schwartz F, Gavras H. Genetics of Human Essential Hypertension – Review. *Rev Bras Hipertens* 11:88-93, 2004.
615. DiPetrillo K, Tsaih SW, Sheehan S, Johns C, Kelmenson P, Gavras H, Churchill GA, Paigen B: Genetic analysis of blood pressure in C3H/HeJ and SWR/J mice. *Physiol Genomics* 17:215-220, 2004
616. Gavras H: Adrenergic Receptors in Hypertension and Heart Failure. Report of the Fourth Annual Laragh Conference. *Am J Hypertens* 17:98-99, 2004.
617. Schwartz F, Duka A, Duka I, Cui J, Gavras H. Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression. *Am J Physiol Heart Circ Physiol* 287: H1957-H-1966, 2004.
618. Gavras I, Gavras H: Progress in stroke prevention: Lessons from the latest trials. *Cardiovasc Rev & Reports* 25: 229-231, 2004.
619. Martin LC, Franco RJS, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barrett BB, Balbi AL, Barsanti R, Padovani C, Gavras H. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. *Am J Hypertens* 17:1163-1169, 2004.
620. Handy, DE, Gavras H. Hypertension and atherogenesis. In: Molecular Mechanisms of Atherosclerosis. Joseph Loscalzo, editor, Published by Taylor & Francis, Abingdon, Oxon, UK, pp 195-207, 2005.
621. Gavras I, Gavras H. The debate goes on—What is your choice? *Am J Cardiol* 95:53-54, 2005.
622. Cui J, Melista E, Chazaro I, Zhang Y, Zhou X, Manolis AJ, Baldwin CT, Destefano AL, Gavras H. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. *J Hypertens* 23:55-62, 2005.
623. Gavras H. Report on the fifth annual Laragh conference: Interaction of the angiotensin converting enzyme (ACE) with the Renin-Angiotensin System, the Kinin System and Beyond. *Am J Hypertens* 18:1-2, 2005.
624. Manolis AJ, Iraklianos S, Pittaras A, Zaris M, Tsioufis K, Psaltiras G, Psomali D, Foussas S, Gavras I, Gavras H. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. *Am J Hypertens* 18:18-22, 2005.
625. Zhou XF, Cui J, Destefano AL, Chazaro I, Farrer LA, Manolis AJ, Gavras H, Baldwin CT. Polymorphisms in the promoter region of catalase gene and essential hypertension. *Dis Markers* 21:3-7, 2005.
626. Gavras I, Gavras H. ACE Inhibitor Trials: Effects in Hypertension. In: Hypertension: A companion to Brenner and Rectors the kidney, second edition. Editors: Suzanne Oparil, Michael A. Weber. Published by Elsevier Saunders, Philadelphia, PA, pp 388-390, 2005.

627. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J: Independence and reproducibility across microarray platforms. *Nat Methods* 2:337-344, 2005.
628. Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, Gavras H. Age-related changes of bradykinin B<sub>1</sub> and B<sub>2</sub> receptors in rat heart. *Am J Physiol Heart Circ Physiol* 289:H202-H205, 2005.
629. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, Gavras H, Baldwin CT. Association of NEDD4L ubiquitin ligase with essential hypertension. *Hypertension* 46:488-491, 2005.
630. Duka A, Schwartz F, Duka I, Johns C, Melista E, Gavras I, Gavras H. A novel Gene (Cmya3) induced in the heart by angiotensin II dependent but not salt dependent hypertension in mice. *Am J Hypertens* 18: 230A, 2005 (Abstract).
631. Ignjacev-Lazich I, Kintsurashvili E, Johns C, Vitseva O, Duka A, Shenouda S, Gavras I, Gavras H. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. *Am J Physiol Heart Circ Physiol* 289: H1814-H1820, 2005.
632. Duka A, Schwartz F, Duka I, Johns C, Melista E, Gavras I, Gavras H. A novel Gene (Cmya3) induced in the heart by angiotensin II dependent but not salt dependent hypertension in mice. *Am J Hypertens* 19: 275-281, 2006.
633. Nguyen GH, Nguyen NC, Storm N, Gange C, Gavras H, Smith CL. Targeted cDNA differential display (TcDD). *Biomol Eng* 23:41-54, 2006.
634. Ribeiro AB, Gavras H. Angiotensin II antagonists – Clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. *Arq Bras Endocrinol Metab* 50:327-333, 2006.
635. Triantafyllidi H, Kintsurashvili E, Johns C, Gavras I, Gavras H. Central plasmid antisense administration reduces blood pressure inhibiting alpha2B adrenoceptor gene expression in spontaneously hypertensive rats in vivo. *Hellenic J Cardiol* 47:144-149, 2006.
636. Duka A, Duka I, Gao G, Shenouda S, Gavras I, Gavras H: Role of bradykinin B<sub>1</sub> and B<sub>2</sub> receptors in normal blood pressure regulation. *Am J Physiol Endocrinol Metab* 291:E268-E274, 2006.
637. Brunner HR, Gavras H: Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7). *J Hypertens* 24:1919-1920, 2006.

638. Martin LC, Franco RJ, Gavras I, Matsubara BB, Okoshi K, Zanati SG, Caramori JT, Barretti P, Balbi AL, Gavras H. Is 44-Hour Better than 24-Hour Ambulatory Blood Pressure Monitoring in Hemodialysis? *Kidney Blood Press Res* 29: 273-279, 2006.
639. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K: The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. *J Clin Invest* 116:1913-1923, 2006.
640. Shenouda SM, Johns C, Gavras I, Gavras H: Long-Term Inhibition of the Central alpha(2B)-Adrenergic Receptor Gene Via Recombinant AAV-Delivered Antisense in Hypertensive Rats. *Am J Hypertens* 19:1135-1143, 2006.
641. Cardoso de Carvalho F, Bregagnollo E, Santos Silva V, Brunie A, da Silva Franco RJ, Martin LC, Gavras I, Gavras H: Frequency of coronary artery disease in patients with renal artery stenosis without clinical manifestations of coronary insufficiency. *Am J Hypertens* 19:1125-1128, 2006.
642. Sun B, Kintsurashvili E, Ona D, Ignjacev-Lazich I, Gavras I, Gavras H: Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. *Vascul Pharmacol* 46:367-372, 2007.
643. Gavras H, Brunner HR: Evolution and Hypertension: Is the Renin System Necessary. *Hypertension* 49:e36, 2007 (Letter to the Editor).
644. Kintsurashvili E, Shenouda S, Ona D, Ona L, Ahmad S, Ravid K, Coelho J, Gavras I, Gavras H. Hypertension in transgenic mice with brain-selective overexpression of the  $\alpha_{2B}$ -adrenoceptor. Presented at the 2007 Meeting on Clinical Cardiovascular Genomics at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (Abstract).
645. Gavras H, Gavras I. Vasopressin Inhibitors. In: Hypertension Primer, Fourth Edition. Editors: Joseph L. Izzo, Jr., Domenic A. Sica and Henry R. Black. Published by Lippincott Williams & Wilkins, Philadelphia, PA, pp 474-476, 2008.
646. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H: Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. *Hypertension* 51:1352-1357, 2008.
647. Silva VS, Martin LC, Franco RJ, Carvalho FC, Bregagnollo EA, Castro JH, Gavras I, Gavras H: Pleiotropic Effects of Statins May Improve Outcomes in Atherosclerotic Renovascular Disease. *Am J Hypertens* 21:1163-1168, 2008.
648. Kintsurashvili E, Shenouda S, Ona D, Ona L, Ahmad S, Ravid K, Gavras I, Gavras H: Hypertension in transgenic mice with brain-selective overexpression of the alpha<sub>2B</sub>-adrenoceptor. *Am J Hypertens* 22:41-45, 2009.
649. Gavras, H. Pathogenesis of Hypertension: A Review. *J Med Sci* 2:25-28, 2009.
650. Gavras, H. Has the Time Come for a Fixed Combination of Renin Inhibitor with ACEI or ARB? *AJH (Suppl 2)* p. 3, 2009 (Abstract).
651. Ahmad S, Cesana F, Lamperti E, Gavras H, Yu J: Attenuation of angiotensin II-induced hypertension and cardiac hypertrophy in transgenic mice overexpressing a type 1 receptor mutant. *Am J Hypertens* 22:1320-1325, 2009.
652. Milka Koupenova, Hillary Johnston-Cox, Alexander Vezeridis, Haralambos Gavras, Dan

Yang, Vassilis Zannis and Katya Ravid. A2b Adenosine Receptor Regulates Hyperlipidimia and Atherosclerosis. *Circulation* 125:354-463, 2012.

653. Lucero HA, Kintsurashvili E, Marketou ME, Gavras H: Cell signaling, internalization and nuclear localization of the angiotensin converting enzyme in smooth muscle cells and endothelial cells. *J Biol Chem* 285:5555-5568, 2010.
654. McCalmon SA, Desjardins DM, Ahmad S, Davidoff KS, Snyder CM, Sato K, Ohashi K, Kielbasa OM, Mathew M, Ewen EP, Walsh K, Gavras H, Naya FJ: Modulation of Angiotensin II-Mediated Cardiac Remodeling by the MEF2A Target Gene Xirp2. *Circ Res* 106:952-960, 2010.
655. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H: Cardioprotective Effects of a Selective B<sub>2</sub> Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct. *Am J Hypertens* 23:562-568, 2010.
656. Manolis AJ, Marketou ME, Gavras I, Gavras H: Cardioprotective properties of bradykinin: role of the B<sub>2</sub> receptor. *Hypertens Res* 33:772-777, 2010.